View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2016	Feb. 24, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		87,553,024
Entity Public Float			$ 4.0

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 57,063	$ 11,215
Accounts receivable, net of allowance for doubtful accounts of $38,916 and $29,332, respectively	263,327	216,626
Other current assets	107,537	66,895
Total current assets	427,927	294,736
Property and equipment:
Land	411,331	214,138
Building and improvements	2,031,819	1,277,800
Equipment	318,020	141,543
Construction in progress	157,114	195,042
Less accumulated depreciation	(214,589)	(119,470)
Property and equipment, net	2,703,695	1,709,053
Goodwill	2,681,188	2,128,215
Intangible assets, net	83,310	59,575
Deferred tax assets - noncurrent	3,780	49,114
Derivative instruments	73,509
Other assets	51,317	38,515
Total assets	6,024,726	4,279,208
Current liabilities:
Current portion of long-term debt	34,805	45,360
Accounts payable	80,034	91,341
Accrued salaries and benefits	105,068	80,696
Other accrued liabilities	122,958	72,806
Total current liabilities	342,865	290,203
Long-term debt	3,253,004	2,195,384
Deferred tax liabilities - noncurrent	78,520	23,936
Other liabilities	164,859	78,602
Total liabilities	3,839,248	2,588,125
Redeemable noncontrolling interests	17,754	8,055
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 and 90,000,000 shares authorized at December 31, 2016 and 2015, respectively; 86,688,199 and 70,745,746 issued and outstanding as of December 31, 2016 and 2015, respectively	867	707
Additional paid-in capital	2,496,288	1,572,972
Accumulated other comprehensive loss	(549,570)	(104,647)
Retained earnings	220,139	213,996
Total equity	2,167,724	1,683,028
Total liabilities and equity	$ 6,024,726	$ 4,279,208

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Receivable, allowance for doubtful accounts	$ 38,916	$ 29,332
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	90,000,000
Common stock, shares issued	86,688,199	70,745,746
Common stock, shares outstanding	86,688,199	70,745,746

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenue before provision for doubtful accounts	$ 702,888	$ 734,665	$ 756,548	$ 616,813	$ 495,319	$ 479,730	$ 453,660	$ 365,783	$ 2,852,823	$ 1,829,619	$ 1,030,784
Provision for doubtful accounts									(41,909)	(35,127)	(26,183)
Revenue									2,810,914	1,794,492	1,004,601
Salaries, wages and benefits (including equity-based compensation expense of $28,345, $20,472 and $10,058, respectively)									1,541,854	973,732	575,412
Professional fees									185,486	116,463	52,482
Supplies									117,425	80,663	48,422
Rents and leases									73,348	32,528	12,201
Other operating expenses									312,556	206,746	110,654
Depreciation and amortization									135,103	63,550	32,667
Interest expense, net									181,325	106,742	48,221
Debt extinguishment costs									4,253	10,818
Loss on divestiture									178,809
(Gain) loss on foreign currency derivatives									(523)	1,926	(15,262)
Transaction-related expenses									48,323	36,571	13,650
Total expenses									2,777,959	1,629,739	878,447
Income from continuing operations before income taxes	42,438	(115,814)	73,852	32,479	52,518	41,645	49,355	21,205	32,955	164,753	126,154
Provision for income taxes									28,779	53,388	42,922
Income (loss) from continuing operations									4,176	111,365	83,232
Income (loss) from discontinued operations, net of income taxes										111	(192)
Net income									4,176	111,476	83,040
Net loss attributable to noncontrolling interests									1,967	1,078
Net income attributable to Acadia Healthcare Company, Inc.	$ 41,818	$ (117,808)	$ 56,445	$ 25,688	$ 34,566	$ 29,550	$ 33,844	$ 14,594	$ 6,143	$ 112,554	$ 83,040
Basic earnings attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations									$ 0.07	$ 1.65	$ 1.51
Income (loss) from discontinued operations									0	0	0
Net income	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 0.49	$ 0.42	$ 0.50	$ 0.23	0.07	1.65	1.51
Diluted earnings attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations									0.07	1.64	1.50
Income (loss) from discontinued operations									0	0	0
Net income	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 0.49	$ 0.42	$ 0.49	$ 0.23	$ 0.07	$ 1.64	$ 1.50
Weighted-average shares outstanding:
Basic									85,701	68,085	55,063
Diluted									85,972	68,391	55,327

Consolidated Statements of Income (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Equity-based compensation expense	$ 28,345	$ 20,472	$ 10,058

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 4,176	$ 111,476	$ 83,040
Other comprehensive loss:
Foreign currency translation loss	(477,772)	(40,103)	(66,206)
Gain on derivative instruments, net of tax of $29.1 million, $0 and $0, respectively	40,598
Pension liability adjustment, net of tax of $1.3 million, $0.9 million and $0.6 million, respectively	(7,749)	3,826	(2,164)
Other comprehensive loss	(444,923)	(36,277)	(68,370)
Comprehensive (loss) income	(440,747)	75,199	14,670
Comprehensive loss attributable to noncontrolling interests	1,967	1,078
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	$ (438,780)	$ 76,277	$ 14,670

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Gain on derivative instruments, tax	$ 29.1	$ 0.0	$ 0.0
Pension liability adjustment, tax	$ 1.3	$ 0.9	$ 0.6

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Other Comprehensive Loss [Member]	Earnings (Accumulated Deficit) [Member]
Balance at Dec. 31, 2013	$ 480,710	$ 501	$ 461,807		$ 18,402
Balance, shares at Dec. 31, 2013		50,071,000
Common stock issued under stock incentive plans	570	$ 2	568
Common stock issued under stock incentive plans, shares		259,000
Common stock withheld for minimum statutory taxes	(4,669)		(4,669)
Equity-based compensation expense	10,058		10,058
Excess tax benefit from equity awards	4,617		4,617
Issuance of common stock, net	374,431	$ 89	374,342
Issuance of common stock, net, shares		8,882,000
Other	578		578
Other comprehensive loss	(68,370)			$ (68,370)
Net (loss) attributable to Acadia Healthcare Company, Inc. stockholders	83,040				83,040
Balance at Dec. 31, 2014	880,965	$ 592	847,301	(68,370)	101,442
Balance, shares at Dec. 31, 2014		59,212,000
Common stock issued under stock incentive plans	$ 1,815	$ 4	1,811
Common stock issued under stock incentive plans, shares	214,079	384,000
Common stock withheld for minimum statutory taxes	$ (9,577)		(9,577)
Equity-based compensation expense	20,472		20,472
Excess tax benefit from equity awards	309		309
Issuance of common stock, net	711,517	$ 111	711,406
Issuance of common stock, net, shares		11,150,000
Other	1,250		1,250
Other comprehensive loss	(36,277)			(36,277)
Net (loss) attributable to Acadia Healthcare Company, Inc. stockholders	112,554				112,554
Balance at Dec. 31, 2015	$ 1,683,028	$ 707	1,572,972	(104,647)	213,996
Balance, shares at Dec. 31, 2015	70,745,746	70,746,000
Common stock issued under stock incentive plans	$ 1,384	$ 5	1,379
Common stock issued under stock incentive plans, shares	57,397	408,000
Common stock withheld for minimum statutory taxes	$ (10,230)		(10,230)
Equity-based compensation expense	28,345		28,345
Issuance of common stock, net	901,979	$ 155	901,824
Issuance of common stock, net, shares		15,534,000
Other	1,998		1,998
Other comprehensive loss	(444,923)			(444,923)
Net (loss) attributable to Acadia Healthcare Company, Inc. stockholders	6,143				6,143
Balance at Dec. 31, 2016	$ 2,167,724	$ 867	$ 2,496,288	$ (549,570)	$ 220,139
Balance, shares at Dec. 31, 2016	86,688,199	86,688,000

Consolidated Statements of Cash Flows $ in Thousands, £ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Operating activities:
Net income	$ 4,176	$ 111,476	$ 83,040
Adjustments to reconcile net income to net cash provided by continuing operating activities:
Depreciation and amortization	135,103	63,550	32,667
Amortization of debt issuance costs	10,324	6,709	3,198
Equity-based compensation expense	28,345	20,472	10,058
Deferred income tax expense	28,647	43,613	7,215
(Income) loss from discontinued operations, net of taxes		(111)	192
Debt extinguishment costs	4,253	10,818
Loss on divestiture	178,809
(Gain) loss on foreign currency derivatives	(523)	1,926	(15,262)
Other	4,715	1,615	488
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(15,718)	(24,954)	(15,110)
Other current assets	(20,648)	(2,717)	(2,011)
Other assets	(4,354)	(8,021)	(6,513)
Accounts payable and other accrued liabilities	22,693	6,868	2,793
Accrued salaries and benefits	(8,572)	1,658	11,980
Other liabilities	4,484	9,236	2,749
Net cash (used in) provided by continuing operating activities	371,734	242,138	115,484
Net cash used in discontinued operating activities	(10,256)	(1,735)	(198)
Net cash provided by operating activities	361,478	240,403	115,286
Investing activities:
Cash paid for acquisitions, net of cash acquired	(683,455)	(574,777)	(738,702)
Cash paid for capital expenditures	(307,472)	(276,047)	(113,244)
Cash paid for real estate acquisitions	(40,757)	(26,622)	(23,177)
Settlement of foreign currency derivatives	523	(1,926)	15,262
Cash received on divestitures	373,266
Other	(2,470)	(5,099)	(913)
Net cash used in investing activities	(660,365)	(884,471)	(860,774)
Financing activities:
Borrowings on long-term debt	1,480,000	1,150,000	542,500
Borrowings on revolving credit facility	179,000	468,000	230,500
Principal payments on revolving credit facility	(337,000)	(310,000)	(284,000)
Principal payments on long-term debt	(49,941)	(31,965)	(7,695)
Repayment of assumed debt	(1,348,389)	(904,467)
Repayment of long-term debt	(200,594)	(97,500)
Payment of debt issuance costs	(36,649)	(26,421)	(12,993)
Payment of premium on senior notes		(7,480)
Issuances of common stock, net	685,097	331,308	374,431
Common stock withheld for minimum statutory taxes, net	(8,846)	(7,762)	(4,099)
Excess tax benefit from equity awards		309	4,617
Cash paid for contingent consideration			(5,000)
Other	(3,837)	(420)	(289)
Net cash provided by (used in) financing activities	358,841	563,602	837,972
Effect of exchange rate changes on cash	(14,106)	(2,359)	(3,013)
Net increase (decrease) in cash and cash equivalents	45,848	(82,825)	89,471
Cash and cash equivalents at beginning of the period	11,215	94,040	4,569
Cash and cash equivalents at end of the period	57,063	11,215	94,040
Supplemental Cash Flow Information:
Cash paid for interest	161,146	87,034	36,776
Cash paid for income taxes	15,483	6,911	32,257
Significant Non-Cash Transactions:
Contingent consideration issued in connection with acquisition			1,467
Effect of acquisitions:
Assets acquired, excluding cash	2,516,880	1,988,634	819,518
Liabilities assumed	(1,616,543)	(1,024,515)	(78,849)
Issuance of common stock in connection with acquisition	(216,882)	(380,210)
Redeemable noncontrolling interest resulting from acquisitions		(9,132)
Prior year deposits paid for acquisitions			(500)
Contingent consideration issued in connection with acquisition			(1,467)
Cash paid for acquisitions, net of cash acquired	$ 683,455	$ 574,777	$ 738,702

Description of Business and Basis of Presentation	12 Months Ended
Description of Business and Basis of Presentation	Dec. 31, 2016
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation *Description of Business* Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (“U.S.”), the United Kingdom (“U.K.”) and Puerto Rico. At December 31, 2016, the Company operated 573 behavioral healthcare facilities with approximately 17,100 beds in 39 states, the U.K. and Puerto Rico. *Basis of Presentation* The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its’ direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The majority of the Company’s expenses are “cost of revenue” items. Costs that could be classified as general and administrative expenses include the Company’s corporate office costs, which were $86.8 million, $68.3 million and $36.9 million for the years ended December 31, 2016, 2015 and 2014, respectively. Certain reclassifications have been made to prior years to conform to the current year presentation.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, cash and cash equivalent balances may exceed federally insured limits. Management believes that the Company mitigates any risks by depositing cash and investing in cash equivalents with major financial institutions.

Revenue and Accounts Receivable

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. The Company receives payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, Clinical Commissioning Groups (“CCGs”) and Local Authorities); and (v) individual patients and clients. Revenue is recorded in the period in which services are provided at established billing rates less contractual adjustments based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates.

The following table presents the percentage of revenue before provision for doubtful accounts generated by each payor type:


	Year Ended December 31,
	2016			2015			2014
Commercial		18.7	%		23.1	%		23.0	%
Medicare		9.4			11.7			19.4
Medicaid		25.4			33.3			38.3
U.K. public funded sources		35.8			19.5			14.5
Self-Pay		9.4			9.6			2.5
Other		1.3			2.8			2.3

Revenue before provision for doubtful accounts		100	%		100	%		100	%

On a combined basis, revenue related to the Medicare and Medicaid programs were 35%, 45% and 58% of all revenue before provision for doubtful accounts for the years ended December 31, 2016, 2015 and 2014, respectively. The Company’s concentration of credit risk from other payors is reduced by the large number of payors and their geographic dispersion. The Company generated approximately 38% and 20% of its revenue for the years ended December 31, 2016 and 2015, respectively, from facilities located in the U.K. and approximately 15% and 12% of its revenue from facilities located in the U.K. and Arkansas, respectively, for the year ended December 31, 2014.

Allowance for Contractual Discounts

The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the allowance for contractual discounts on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s cost report receivables were $7.4 million and $4.2 million at December 31, 2016 and 2015, respectively, and were included in other current assets in the consolidated balance sheets. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount. The net adjustments to estimated cost report settlements resulted in increases to revenue of $0.7 million, $1.9 million and $0.3 million for the years ended December 31, 2016, 2015 and 2014, respectively.

Management believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of wrongdoing. While no such regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties and exclusion from the Medicare and Medicaid programs.

Allowance for Doubtful Accounts

The Company’s ability to collect outstanding patient receivables from third-party payors is critical to its operating performance and cash flows. The primary collection risk with regard to patient receivables relates to uninsured patient accounts or patient accounts for which primary insurance has paid, but the portion owed by the patient remains outstanding. The Company estimates uncollectible accounts and establishes an allowance for doubtful accounts in order to adjust accounts receivable to estimated net realizable value. In evaluating the collectability of accounts receivable, the Company considers a number of factors, including the age of the accounts, historical collection experience, current economic conditions, and other relevant factors. Accounts receivable that are determined to be uncollectible based on the Company’s policies are written off to the allowance for doubtful accounts. Significant changes in payor mix or business office operations could have a significant impact on the Company’s results of operations and cash flows.

A summary of activity in the Company’s allowance for doubtful accounts is as follows (in thousands):


	Balance at Beginning of Period		Additions Charged to Costs and Expenses		Accounts Written Off, Net of Recoveries			Balance at End of Period
Year ended December 31, 2014	$	18,345	$	26,183	$	(22,079	)	$	22,449
Year ended December 31, 2015		22,449		35,127		(28,244	)		29,332
Year ended December 31, 2016		29,332		41,909		(32,325	)		38,916

Charity Care

The Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive based on Company policies and federal and state poverty thresholds. The costs of providing charity care services were $7.1 million, $4.6 million and $2.5 million for the years ended December 31, 2016, 2015 and 2014, respectively. The estimated cost of charity care services was determined using a ratio of cost to gross charges determined from our most recently filed Medicare cost reports and applying that ratio to the gross charges associated with providing charity care for the period.

Insurance

The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. Effective September 1, 2016, a portion of the Company’s professional liability risk is insured through a wholly-owned insurance subsidiary. The Company’s wholly-owned insurance subsidiary insures the Company for professional liability losses up to $52.0 million in the aggregate. The insurance subsidiary has obtained reinsurance with unrelated commercial insurers for professional liability risks of $50.0 million in excess of a retention level of $2.0 million. The reserve for professional and general liability risks was estimated based on historical claims, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. The professional and general liability reserve was $52.3 million as of December 31, 2016, of which $11.7 million was included in other accrued liabilities and $40.6 million was included in other long-term liabilities. The professional and general liability reserve was $41.9 million as of December 31, 2015, of which $10.5 million was included in other accrued liabilities and $31.4 million was included in other long-term liabilities. The Company estimates receivables for the portion of professional and general liability reserves that are recoverable under the Company’s insurance policies. Such receivable was $25.9 million as of December 31, 2016, of which $6.5 million was included in other current assets and $19.4 million was included in other assets, and such receivable was $21.3 million as of December 31, 2015, of which $5.3 million was included in other current assets and $16.0 million was included in other assets.

The Company’s statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $16.6 million as of December 31, 2016, of which $10.0 million was included in accrued salaries and benefits and $6.6 million was included in other long-term liabilities, and such liability was $14.7 million as of December 31, 2015, of which $7.5 million was included in accrued salaries and benefits and $7.2 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.

Property and Equipment and Other Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $134.8 million, $63.0 million and $32.1 million for the years ended December 31, 2016, 2015 and 2014, respectively.

The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful lives, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows.

Goodwill and Indefinite-Lived Intangible Assets

The Company’s goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate that the carrying value of a reporting unit may not be recoverable. The Company has two operating segments, U.S. Facilities and U.K. Facilities, for segment reporting purposes, each of which represents a reporting unit for purposes of the Company’s goodwill impairment test. Potential impairment is noted for a reporting unit if its carrying value exceeds the fair value of the reporting unit. For a reporting unit with potential impairment of goodwill, the Company determines the implied fair value of goodwill. If the carrying value of goodwill exceeds its implied fair value, an impairment loss is recorded. The Company’s annual impairment tests of goodwill and other indefinite-lived intangibles in 2016, 2015 and 2014 resulted in no impairment charges.

Other Current Assets

Other current assets consisted of the following (in thousands):


	As of December 31,
	2016		2015
Other receivables	$	44,975	$	17,518
Prepaid expenses		27,455		21,817
Income taxes receivable		11,714		6,540
Workers’ compensation deposits – current portion		10,000		7,500
Insurance receivable – current portion		6,472		5,290
Inventory		4,633		4,681
Other		2,288		3,549

Other current assets	$	107,537	$	66,895

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):


	As of December 31,
	2016		2015
Accrued expenses	$	37,323	$	17,921
Accrued interest		33,616		26,132
Unearned income		28,805		446
Insurance liability – current portion		11,672		10,490
Accrued property taxes		2,732		2,951
Other		8,283		7,499
Income taxes payable		527		7,367

Other accrued liabilities	$	122,958	$	72,806

Stock Compensation

The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation—Stock Compensation.” The Company uses the Black-Scholes valuation model to determine grant-date fair value for equity awards and uses straight-line amortization of share-based compensation expense over the requisite service period of the respective awards.

Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with FASB ASC 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options, non-vested shares and warrants, to the extent such securities have a dilutive effect on earnings per share.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

The Company reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

Recent Accounting Pronouncements

In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, “Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). ASU 2017-04 simplifies the measurement of goodwill by eliminating the requirement to calculate the implied fair value of goodwill (step 2 of the current impairment test) to measure the goodwill impairment charge. Instead, entities will record impairment charges based on the excess of a reporting unit’s carrying amount over its fair value. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. Management is evaluating the impact of ASU 2017-04 on the Company’s consolidated financial statements.

In March 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 includes multiple provisions intended to simplify various aspects of the accounting for share-based payments. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Additionally, ASU 2016-09 would permit both public and nonpublic organizations to adopt the new standard early. Management does not anticipate ASU 2016-09 will have a significant impact on the Company’s consolidated financial statements, but the impact will depend on future changes in the Company’s stock price.

In March 2016, the FASB issued ASU 2016-02, “Leases” (“ASU 2016-02”). ASU 2016-02’s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Additionally, ASU 2016-02 would permit both public and nonpublic organizations to adopt the new standard early. Management believes the primary effect of adopting the new standard will be to record right-of-use assets and obligations for current operating leases.

In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements- Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” which requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date of the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. The Company adopted ASU 2014-15 as of December 31, 2016. There was no impact on the Company’s consolidated financial statements as a result of this adoption.

In May 2014, the FASB and the International Accounting Standards Board issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires companies to exercise more judgment and recognize revenue in accordance with the standard’s core principle by applying the following five steps:

Step 1: Identify the contract with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

ASU 2014-09 also includes a cohesive set of quantitative and qualitative disclosure requirements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from the entity’s contracts with customers.

ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Additionally, ASU 2014-09 would permit both public and nonpublic organizations to adopt the new revenue standard early, but not before the original public organization effective date (that is, annual periods beginning after December 15, 2016). ASU 2014-09 requires retrospective application using either a full retrospective adoption or a modified retrospective adoption approach. Full retrospective adoption requires entities to apply the standard as if it had been in effect since the inception of all its contracts with customers presented in the financial statements. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings at the date of adoption. Management anticipates that the Company will adopt the full retrospective method and does not plan to early adopt ASU 2014-09.

Additionally, the Company anticipates that, as a result of certain changes required by ASU 2014-09, the majority of its provision for doubtful accounts will be recorded as a direct reduction to revenue instead of being presented as a separate line item. Management is continuing to evaluate the impact of ASU 2014-09 on the Company’s consolidated financial statements.

Earnings Per Share

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Earnings Per Share

3. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2016, 2015 and 2014 (in thousands except per share amounts):


	Year Ended December 31,
	2016		2015		2014
Numerator:
Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	6,143	$	112,443	$	83,232
Income (loss) from discontinued operation		—		111		(192	)

Net income attributable to Acadia Healthcare Company, Inc.	$	6,143	$	112,554	$	83,040

Denominator:
Weighted average shares outstanding for basic earnings per share		85,701		68,085		55,063
Effects of dilutive instruments		271		306		264

Shares used in computing diluted earnings per common share		85,972		68,391		55,327

Basic earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	0.07	$	1.65	$	1.51
Income (loss) from discontinued operations		—		—		—

Net income attributable to Acadia Healthcare Company, Inc.:	$	0.07	$	1.65	$	1.51

Diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	0.07	$	1.64	$	1.50
Income (loss) from discontinued operations		—		—		—

Net income attributable to Acadia Healthcare Company, Inc.:	$	0.07	$	1.64	$	1.50

Approximately 1.1 million, 0.8 million and 0.7 million shares of common stock issuable upon exercise of outstanding stock options were excluded from the calculation of diluted earnings per share for the years ended December 31, 2016, 2015 and 2014, respectively, because their effect would have been anti-dilutive.

Acquisitions

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Acquisitions

4. Acquisitions

2016 U.S. Acquisitions

On June 1, 2016, the Company completed the acquisition of Pocono Mountain Recovery Center (“Pocono Mountain”), an inpatient psychiatric facility with 108 beds located in Henryville, Pennsylvania, for cash consideration of approximately $25.4 million. In addition, the Company may be required to make a cash payment of up to $5.0 million under an earn-out agreement, contingent upon achievement by Pocono Mountain of certain operating performance targets for the one-year period ending May 31, 2017.

On May 1, 2016, the Company completed the acquisition of TrustPoint Hospital (“TrustPoint”), an inpatient psychiatric facility with 100 beds located in Murfreesboro, Tennessee, for cash consideration of approximately $62.7 million.

On April 1, 2016, the Company completed the acquisition of Serenity Knolls (“Serenity Knolls”), an inpatient psychiatric facility with 30 beds located in Forest Knolls, California, for cash consideration of approximately $9.7 million.

Priory

On February 16, 2016, the Company completed the acquisition of Priory Group No. 1 Limited (“Priory”) for a total purchase price of approximately $2.2 billion, including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of its common stock to shareholders of Priory. Priory was the leading independent provider of behavioral healthcare services in the U.K. operating 324 facilities with approximately 7,100 beds at February 16, 2016.

The Competition and Markets Authority (the “CMA”) in the U.K. reviewed the Company’s acquisition of Priory. On July 14, 2016, the CMA announced that the Company’s acquisition of Priory was referred for a phase 2 investigation unless the Company offered acceptable undertakings to address the CMA’s competition concerns relating to the provision of behavioral healthcare services in certain markets. On July 28, 2016, the CMA announced that the Company had offered undertakings to address the CMA’s concerns and that, in lieu of a phase 2 investigation, the CMA would consider the Company’s undertakings.

On October 18, 2016, the Company signed a definitive agreement with BC Partners (“BC Partners”) for the sale of 21 existing U.K. behavioral health facilities and one de novo behavioral health facility with an aggregate of approximately 1,000 beds (collectively, the “U.K. Disposal Group”). On November 10, 2016, the CMA accepted the Company’s undertakings to sell the U.K. Disposal Group to BC Partners and confirmed that the divestiture satisfied the CMA’s concerns about the impact of the Company’s acquisition of Priory on competition for the provision of behavioral healthcare services in certain markets in the U.K. As a result of the CMA’s acceptance of the undertakings, the Company’s acquisition of Priory was not referred for a phase 2 investigation. On November 30, 2016, the Company completed the sale of the U.K. Disposal Group to BC Partners for £320 million cash (the “U.K. Divestiture”).

In conjunction with the sale, the Company recorded a loss on divestiture of $175.0 million in the consolidated statements of income for the year ended December 31, 2016. The loss on divestiture consisted of an allocation of goodwill to the U.K. Disposal Group of $106.9 million, loss on the sale of properties of $42.0 million and estimated transaction-related expenses of $26.1 million. The allocation of goodwill was based on the fair value of the U.K. Disposal Group relative to the total fair value of the Company’s U.K. Facilities segment.

The consolidated statements of income for the year ended December 31, 2016 include revenue of $154.7 million and income from continuing operations before income taxes of $81.2 million related to the U.K. Disposal Group excluding the loss on divestiture. The consolidated statements of income for the year ended December 31, 2015 include revenue of $58.5 million and income from continuing operations before income taxes of $17.0 million related to the U.K. Disposal Group excluding the loss on divestiture.

2015 U.S. Acquisitions

On December 1, 2015, the Company completed the acquisition of certain facilities from MMO Behavioral Health Systems (“MMO”), including two acute inpatient behavioral health facilities with a total of 80 beds located in Jennings and Covington, Louisiana, for cash consideration of approximately $20.2 million.

On November 1, 2015, the Company completed the acquisitions of (i) Discovery House-Group Inc. (“Discovery House”) for cash consideration of approximately $118.3 million and (ii) Duffy’s Napa Valley Rehab (“Duffy’s”) for cash consideration of approximately $29.6 million. Discovery House operates 19 comprehensive treatment centers located in four states. Duffy’s is a substance abuse facility with 61 beds located in Calistoga, California.

On August 31, 2015, the Company completed the acquisition of a controlling interest in Southcoast Behavioral (“Southcoast”), an inpatient psychiatric facility located in Fairhaven, Massachusetts. The Company owns 75% of the equity interests in the facility. The value of the 25% noncontrolling interest is approximately $9.2 million.

On July 1, 2015, the Company completed the acquisition of the assets of Belmont Behavioral Health (“Belmont”), an inpatient psychiatric facility with 147 beds located in Philadelphia, Pennsylvania for cash consideration of approximately $39.0 million which consists of $35.0 million base purchase price and a working capital settlement of $4.0 million.

On March 1, 2015, the Company acquired the stock of Quality Addiction Management, Inc. (“QAM”) for cash consideration of approximately $54.8 million. QAM operates seven comprehensive treatment centers located in Wisconsin.

On February 11, 2015, the Company completed the acquisition of CRC Health Group, Inc. (“CRC”) for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness of $904.5 million. CRC was a leading provider of treatment services related to substance abuse and other addiction and behavioral disorders operating 35 inpatient facilities with over 2,400 beds and 81 comprehensive treatment centers located in 30 states at the acquisition date.

2015 U.K. Acquisitions

On November 1, 2015, the Company completed the acquisition of Cleveland House (“Cleveland House”), an inpatient psychiatric facility with 32 beds located in England, for cash consideration of approximately $10.3 million.

On October 1, 2015, the Company completed the acquisition of Meadow View (“Meadow View”), an inpatient psychiatric facility with 28 beds located in England, for cash consideration of approximately $6.8 million.

On September 1, 2015, the Company completed the acquisitions of (i) three facilities from The Danshell Group (“Danshell”) for approximately $59.8 million, (ii) two facilities from Health and Social Care Partnerships (“H&SCP”) for approximately $26.2 million and (iii) Manor Hall (“Manor Hall”) for approximately $14.0 million. The inpatient psychiatric facilities acquired from Danshell have an aggregate of 73 beds and are located in England. The inpatient psychiatric facilities acquired from H&SCP have an aggregate of 50 beds and are located in England. Manor Hall has 26 beds and is located in England.

On July 1, 2015, the Company completed the acquisition of The Manor Clinic (“The Manor Clinic”), a substance abuse facility with 15 beds located in England, for cash consideration of approximately $5.9 million.

On June 1, 2015, the Company completed the acquisitions of (i) one facility from Choice Lifestyles (“Choice”) for cash consideration of approximately $25.9 million and (ii) 15 facilities from Care UK Limited (“Care UK”) for approximately $88.2 million. The inpatient psychiatric facility acquired from Choice has 42 beds and is located in England. The inpatient psychiatric facilities acquired from Care UK have an aggregate of 299 beds and are located in England.

On April 1, 2015, the Company completed the acquisitions of (i) two facilities from Choice for cash consideration of approximately $37.5 million, (ii) Pastoral Care Group (“Pastoral”) for approximately $34.2 million and (iii) Mildmay Oaks f/k/a Vista Independent Hospital (“Mildmay Oaks”) for cash consideration of approximately $14.9 million. The two inpatient psychiatric facilities acquired from Choice have an aggregate of 48 beds and are located in England. Pastoral operates two inpatient psychiatric facilities with an aggregate of 65 beds located in Wales. Mildmay Oaks is an inpatient psychiatric facility with 67 beds located in England.

Summary of Acquisitions

The Company selectively seeks opportunities to expand and diversify its base of operations by acquiring additional facilities. Approximately $319.4 million of the goodwill associated with domestic acquisitions completed in 2016 and 2015 is deductible for federal income tax purposes. The fair values assigned to certain assets and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. Specifically, the Company is further assessing the valuation of certain real property and intangible assets and certain tax matters as well as certain receivables and assumed liabilities of Pocono Mountain, TrustPoint, Serenity Knolls and Priory.

The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the year ended December 31, 2016 in connection with 2016 acquisitions were as follows (in thousands):


	Priory		Other		Total
Cash	$	10,253	$	2,488	$	12,741
Accounts receivable		57,832		4,289		62,121
Prepaid expenses and other current assets		7,921		143		8,064
Property and equipment		1,598,156		35,400		1,633,556
Goodwill		686,149		95,645		781,794
Intangible assets		23,200		338		23,538
Other assets		7,760		47		7,807

Total assets acquired		2,391,271		138,350		2,529,621
Accounts payable		24,203		805		25,008
Accrued salaries and benefits		39,588		797		40,385
Other accrued expenses		48,305		390		48,695
Deferred tax liabilities – noncurrent		59,972		269		60,241
Debt		1,348,389		—		1,348,389
Other liabilities		63,583		30,242		93,825

Total liabilities assumed		1,584,040		32,503		1,616,543

Net assets acquired	$	807,231	$	105,847	$	913,078

The fair values of assets acquired and liabilities assumed during 2015, at the corresponding acquisition dates, were as follows (in thousands):


	CRC		Other		Total
Cash	$	19,599	$	5,334	$	24,933
Accounts receivable		47,035		20,445		67,480
Prepaid expenses and other current assets		26,945		2,555		29,500
Property and equipment		136,163		273,143		409,306
Goodwill		1,039,320		322,017		1,361,337
Intangible assets		37,000		204		37,204
Deferred tax asset-noncurrent		78,664		—		78,664
Other assets		6,478		51		6,529

Total assets acquired		1,391,204		623,749		2,014,953
Accounts payable		4,741		4,961		9,702
Accrued salaries and benefits		14,827		3,200		18,027
Other accrued expenses		38,873		5,782		44,655
Deferred tax liabilities – noncurrent		—		13,541		13,541
Debt		904,467		—		904,467
Other liabilities		34,720		10		34,730

Total liabilities assumed		997,628		27,494		1,025,122

Redeemable noncontrolling interests		—		9,132		9,132

Net assets acquired	$	393,576	$	587,123	$	980,699

Other

The qualitative factors comprising the goodwill acquired in the CRC, QAM, Choice, Pastoral, Mildmay Oaks, Care UK, The Manor Clinic, Belmont, Southcoast, Danshell, H&SCP, Manor Hall, Meadow View, Cleveland House, Duffy’s, Discovery House, MMO, Priory, Serenity Knolls, TrustPoint and Pocono Mountain acquisitions (collectively the “2015 and 2016 Acquisitions”) include efficiencies derived through synergies expected by the elimination of certain redundant corporate functions and expenses, the ability to leverage call center referrals to a broader provider base, coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance, and applying best practices throughout the combined companies.

Transaction-related expenses comprised the following costs for the years ended December 31, 2016, 2015 and 2014 (in thousands):


	Year Ended December 31,
	2016		2015		2014
Legal, accounting and other fees	$	21,058	$	17,768	$	12,836
Advisory and financing commitment fees		14,850		10,337		—
Severance and contract termination costs		12,415		8,466		814

	$	48,323	$	36,571	$	13,650

Pro Forma Information

The consolidated statements of income for the year ended December 31, 2016 included revenue of $1.5 billion and income from continuing operations before income taxes of $74.8 million for acquisitions completed in 2016. The consolidated statements of income for the year ended December 31, 2015 included revenue of $552.1 million and income from continuing operations before income taxes of $204.1 million for acquisitions completed in 2015.

The following table provides certain unaudited pro forma financial information for the Company as if the 2015 and 2016 Acquisitions and the U.K. Divestiture had been completed as of January 1, 2015 (in thousands):


	Year Ended December 31,
	2016		2015
Revenue	$	2,765,221	$	2,715,749

Income from continuing operations, before income taxes	$	173,707	$	113,297

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Other Intangible Assets

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Other Intangible Assets

5. Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following as of December 31, 2016 and 2015 (in thousands):


	Gross Carrying Amount				Accumulated Amortization
	December 31, 2016		December 31, 2015		December 31, 2016			December 31, 2015
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(1,750	)
Non-compete agreements		1,147		1,247		(1,147	)		(1,247	)

		3,247		3,347		(3,247	)		(2,997	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,228		11,479		—			—
Trade names		57,538		37,800		—			—
Certificates of need		13,544		9,946		—			—

		83,310		59,225		—			—

Total	$	86,557	$	62,572	$	(3,247	)	$	(2,997	)

Amortization expense related to definite-lived intangible assets was $0.4 million, $0.5 million and $0.6 million for the years ended December 31, 2016, 2015 and 2014, respectively. As of December 31, 2016, all the Company’s defined-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

Long-Term Debt

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Long-Term Debt

6. Long-Term Debt

Long-term debt consisted of the following (in thousands):


	December 31, 2016			December 31, 2015
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans	$	400,000		$	500,750
Senior Secured Term B Loans		1,435,450			495,000
Senior Secured Revolving Line of Credit		—			158,000
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			—
9.0% and 9.5% Revenue Bonds		22,175			22,410
Less: unamortized debt issuance costs, discount and premium		(59,816	)		(35,416	)

		3,287,809			2,240,744
Less: current portion		(34,805	)		(45,360	)

Long-term debt	$	3,253,004		$	2,195,384

Amended and Restated Senior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”). The Company has amended the Amended and Restated Credit Agreement from time to time as described in the Company’s prior filings with the Securities and Exchange Commission.

On February 6, 2015, the Company entered into a Seventh Amendment (the “Seventh Amendment”) to the Amended and Restated Credit Agreement. The Seventh Amendment added Citibank, N.A. as an “L/C Issuer” under the Amended and Restated Credit Agreement in order to permit the rollover of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million.

On February 11, 2015, the Company entered into a First Incremental Facility Amendment (the “First Incremental Amendment”) to the Amended and Restated Credit Agreement. The First Incremental Amendment activated a new $500.0 million incremental Term Loan B facility (the “Existing TLB Facility”) that was added to the Amended and Restated Senior Credit Facility, subject to limited conditionality provisions. Borrowings under the Existing TLB Facility were used to fund a portion of the purchase price for the acquisition of CRC.

On April 22, 2015, the Company entered into an Eighth Amendment (the “Eighth Amendment”) to the Amended and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation.

On January 25, 2016, the Company entered into the Ninth Amendment (the “Ninth Amendment”) to the Amended and Restated Credit Agreement. The Ninth Amendment modified certain definitions and provided increased flexibility to the Company in terms of its financial covenants. The Company’s baskets for permitted investments were also increased to provide increased flexibility for it to invest in non-wholly owned subsidiaries, joint ventures and foreign subsidiaries. The Company may now invest in non-wholly owned subsidiaries and joint ventures up to 10.0% of the Company and its subsidiaries’ total assets in any four consecutive fiscal quarter period, and up to 12.5% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The Company may also invest in foreign subsidiaries that are not loan parties up to 10% of the Company and its subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 15% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 25% of the Company and its subsidiaries’ total assets in any fiscal year.

On February 16, 2016, the Company entered into a Second Incremental Facility Amendment (the “Second Incremental Amendment”) to the Amended and Restated Credit Agreement. The Second Incremental Amendment activated a new $955.0 million incremental Term Loan B facility (the “New TLB Facility”) and added $135.0 million to the Term Loan A facility (the “TLA Facility”) to the Amended and Restated Senior Credit Facility, subject to limited conditionality provisions. Borrowings under the New TLB Facility were used to fund a portion of the purchase price for the acquisition of Priory and the fees and expenses for such acquisition and the related financing transactions. Borrowings under the TLA Facility were used to pay down the majority of our $300.0 million revolving credit facility.

On May 26, 2016, the Company entered into a Tranche B-1 Repricing Amendment (the “Tranche B-1 Repricing Amendment”) to the Amended and Restated Credit Agreement. The Tranche B-1 Repricing Amendment reduced the Applicable Rate with respect to the Existing TLB Facility from 3.5% to 3.0% in the case of Eurodollar Rate loans and 2.5% to 2.0% in the case of Base Rate Loans.

On September 21, 2016, the Company entered into a Tranche B-2 Repricing Amendment (the “Tranche B-2 Repricing Amendment”) to the Amended and Restated Credit Agreement. The Tranche B-2 Repricing Amendment reduced the Applicable Rate with respect to the New TLB Facility from 3.75% to 3.0% in the case of Eurodollar Rate loans and 2.75% to 2.0% in the case of Base Rate Loans. In connection with the Tranche B-2 Repricing Amendment, the Company recorded a debt extinguishment charge of $3.4 million, including the discount and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.

On November 22, 2016, the Company entered into a Tenth Amendment (the “Tenth Amendment”) to the Amended and Restated Credit Agreement. The Tenth Amendment, among other things, (i) amended the negative covenant regarding dispositions, (ii) modified the collateral package to release any real property with a fair market value of less than $5.0 million and (iii) changed certain investment, indebtedness and lien baskets.

On November 30, 2016, the Company entered into a Refinancing Facilities Amendment (the “Refinancing Amendment”) to the Amended and Restated Credit Agreement. The Refinancing Amendment increased the Company’s line of credit on its revolving credit facility to $500.0 million from $300.0 million and reduced its TLA Facility to $400.0 million from $600.6 million (together, the “Refinancing Facilities”). In addition, the Refinancing Amendment extended the maturity date for the Refinancing Facilities to November 30, 2021 from February 13, 2019, and lowered the Company’s effective interest rate on the line of credit on its revolving credit facility and TLA Facility by 50 basis points. In connection with the Refinancing Amendment, the Company recorded a debt extinguishment charge of $0.8 million, including the write-off of deferred financing costs, which was recorded in debt extinguishment in the consolidated statements of income.

The Company had $491.7 million of availability under the revolving line of credit and had standby letters of credit outstanding of $8.3 million related to security for the payment of claims required by its workers’ compensation insurance program as of December 31, 2016. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $5.0 million for March 31, 2017 to December 31, 2019, $7.5 million for March 31, 2020 to December 31, 2020, and $10.0 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. The Company is required to repay the Existing TLB Facility in equal quarterly installments of $1.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Existing TLB Facility due on February 11, 2022. The Company is required to repay the New TLB Facility in equal quarterly installments of approximately $2.4 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TLB Facility due on February 16, 2023.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 2.75% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 1.75% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at December 31, 2016. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of December 31, 2016, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.75%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. As of December 31, 2016, the Company was in compliance with such covenants.

Senior Notes

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year.

6.500% Senior Notes due 2024

On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

The indentures governing the 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

9.0% and 9.5% Revenue Bonds

On November 11, 2012, in connection with the acquisition of Park Royal, the Company assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively. The 9.0% bonds in the amount of $7.5 million have a maturity date of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. As of December 30, 2016 and December 31, 2015, $2.3 million was recorded within other assets on the consolidated balance sheets related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the revenue bonds using the effective interest method.

Debt Issuance Costs

Debt issuance costs are deferred and amortized to interest expense over the term of the related debt. Debt issuance costs at December 31, 2016 were $59.0 million, net of accumulated amortization of $21.6 million. Debt issuance costs at December 31, 2015 were $37.6 million, net of accumulated amortization of $12.6 million. Amortization expense related to debt issuance costs, which is reported as interest expense, was $10.8 million and $7.1 million, respectively, for the years ended December 31, 2016 and 2015. Estimated amortization of debt issuance costs for the years ending December 31, 2017, 2018, 2019, 2020 and 2021 is $9.3 million, $9.7 million, $10.0 million, $10.4 million and $10.2 million, respectively.

Other

The aggregate maturities of long-term debt as of December 31, 2016 were as follows (in thousands):


2017	$	34,805
2018		34,830
2019		34,855
2020		44,880
2021		474,910
Thereafter		2,723,345

Total	$	3,347,625

Equity	12 Months Ended
Equity	Dec. 31, 2016
Equity [Abstract]
Equity	7. Equity *Preferred Stock* The Company’s amended and restated certificate of incorporation provides that up to 10,000,000 shares of preferred stock may be issued. The Board of Directors has the authority to issue preferred stock in one or more series and to fix for each series the voting powers (full, limited or none), and the designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions on the stock and the number of shares constituting any series and the designations of this series, without any further vote or action by the stockholders. *Common Stock* On March 3, 2016, the Company held a Special Meeting of Stockholders, where the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 90,000,000 to 180,000,000 (the “Amendment”). On March 3, 2016, the Company filed the Amendment with the Secretary of State of the State of Delaware. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters on which stockholders may vote. There are no preemptive, conversion, redemption or sinking fund provisions applicable to shares of the Company’s common stock. In the event of liquidation, dissolution or winding up, holders of the Company’s common stock are entitled to share ratably in the assets available for distribution, subject to any prior rights of any holders of preferred stock then outstanding. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the Amended and Restated Senior Credit Facility imposes restrictions on the Company’s ability to pay dividends. *Equity Offerings* On February 11, 2015, the Company completed the acquisition of CRC for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness. On May 11, 2015, the Company completed the offering of 5,175,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $66.50 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $12.0 million and additional offering-related costs of $0.8 million, were $331.3 million. The Company used the net offering proceeds to repay outstanding indebtedness and fund acquisitions. On January 12, 2016, the Company completed the offering of 11,500,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $61.00 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $15.8 million and additional offering-related costs of $0.7 million, were $685.0 million. The Company used the net offering proceeds to fund a portion of the purchase price for the acquisition of Priory. On February 16, 2016, the Company completed the acquisition of Priory for a total purchase price of approximately $2.2 billion including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of our common stock to shareholders of Priory.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Equity-Based Compensation

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity-Based Compensation

8. Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). As of December 31, 2016, a maximum of 8,200,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 4,645,213 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the date of grant.

The Company recognized $28.3 million, $20.5 million and $10.1 million in equity-based compensation expense for the years ended December 31, 2016, 2015 and 2014, respectively. As of December 31, 2016, there was $51.0 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.2 years.

As of December 31, 2016, there were no warrants outstanding and exercisable. The Company recognized a deferred income tax benefit of $10.7 million and $8.4 million for the years ended December 31, 2016 and 2015, respectively, related to equity-based compensation expense. The actual tax benefit realized from stock options exercised during the years ended December 31, 2015 and 2014 was $0.3 million and $4.6 million, respectively.

Stock option activity during 2015 and 2016 was as follows (aggregate intrinsic value in thousands):


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2015		737,422		$	32.19		8.09	$	14,512
Options granted		204,700			63.07		9.21		1,724
Options exercised		(214,079	)		42.75		N/A		9,890
Options cancelled		(33,300	)		46.53		N/A		N/A

Options outstanding at December 31, 2015		694,743			42.87		7.70		20,717
Options granted		503,850			57.98		9.28		297
Options exercised		(57,397	)		31.92		N/A		1,530
Options cancelled		(140,250	)		57.13		N/A		N/A

Options outstanding at December 31, 2016		1,000,946		$	49.42		7.80	$	8,166

Options exercisable at December 31, 2015		106,330		$	36.41		5.83	$	4,968

Options exercisable at December 31, 2016		288,959		$	42.81		6.22	$	6,111

Restricted stock activity during 2015 and 2016 was as follows:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2015		722,028		$	39.77
Granted		503,052			62.67
Cancelled		(44,900	)		49.55
Vested		(235,618	)		34.93

Unvested at December 31, 2015		944,562		$	52.74
Granted		387,347			55.38
Cancelled		(122,178	)		57.02
Vested		(365,312	)		47.18

Unvested at December 31, 2016		844,419		$	55.76

Restricted stock unit activity during 2015 and 2016 was as follows:


	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2015		125,113		$	38.73
Granted		217,994			61.77
Cancelled		—			—
Vested		(125,023	)		32.38

Unvested at December 31, 2015		218,084		$	56.97
Granted		230,750			56.95
Cancelled		—			—
Vested		(175,235	)		52.71

Unvested at December 31, 2016		273,599		$	59.68

The grant-date fair value of the Company’s stock options is estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2016 and 2015:


	December 31, 2016			December 31, 2015
Weighted average grant-date fair value of options	$	18.96		$	21.78
Risk-free interest rate		1.4	%		1.5	%
Expected volatility		33	%		35	%
Expected life (in years)		5.5			5.5

The Company’s estimate of expected volatility for stock options is based upon the volatility of guideline companies given the lack of sufficient historical trading experience of the Company’s common stock. The risk-free interest rate is the approximate yield on U.S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

9. Income Taxes

Income tax expense (benefit) from continuing operations consists of the following for the periods presented (in thousands):


	Year Ended December 31,
	2016			2015			2014
Current:
Federal	$	572		$	(218	)	$	30,834
State		(863	)		4,078			3,959
Foreign		423			5,915			914

Total current		132			9,775			35,707
Deferred:
Federal		45,077			40,635			2,667
State		1,491			5,349			353
Foreign		(17,921	)		(2,371	)		4,195

Total deferred provision		28,647			43,613			7,215

Provision for (benefit from) income taxes	$	28,779		$	53,388		$	42,922

A reconciliation of the U.S. federal statutory rate, from continuing operations, to the effective tax rate is as follows for the periods presented:


	Year Ended December 31,
	2016			2015			2014
U.S. federal statutory rate on income before income taxes		35.0	%		35.0	%		35.0	%
Impact of foreign operations		(13.5	)		(10.0	)		(4.2	)
Impact of foreign divestiture		39.2			—			—
Effects of statutory rate change		(14.5	)		—			—
State income taxes, net of federal tax effect		7.5			4.8			2.3
Permanent differences		8.3			4.2			1.1
Transaction related items		25.9			—			—
Change in valuation allowance		2.8			1.2			(0.1	)
Unrecognized tax benefit release		(7.2	)		—			—
Other		3.8			(2.8	)		(0.1	)

Effective income tax rate		87.3	%		32.4	%		34.0	%

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities of the Company at December 31, 2016 and December 31, 2015 were as follows (in thousands):


	December 31,
	2016			2015
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	37,638		$	47,695
Bad debt allowance		15,381			14,050
Accrued compensation and severance		23,379			20,150
Pension reserves		697			536
Insurance reserves		17,468			15,449
Leases		2,926			2,675
Accrued expenses		—			5,324
Other assets		2,038			3,551

Total gross deferred tax assets		99,527			109,430
Less: valuation allowance		(16,031	)		(16,571	)

Deferred tax assets		83,496			92,859
Deferred tax liabilities:
Fixed asset basis difference		(45,510	)		(11,392	)
Prepaid items		(1,324	)		(3,113	)
Intangible assets		(77,655	)		(48,918	)
Accrued expenses		(4,531	)		—
Other liabilities		(29,216	)		(4,258	)

Total deferred tax liabilities		(158,236	)		(67,681	)

Total net deferred tax asset (liability)	$	(74,740	)	$	25,178

The Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. As of December 31, 2016 and 2015, the Company carried a valuation allowance against deferred tax assets of $16.0 million and $16.6 million, respectively.

The domestic net operating loss carryforwards the Company has acquired for federal net operating loss carryforwards are approximately $28.4 million and $88.0 million as of December 31, 2016 and 2015, respectively. The foreign net operating loss carryforwards as of December 31, 2016 and 2015 are approximately $92.2 million and $14.7 million, respectively, and have no expiration. In addition, the Company has certain foreign tax credits which do not have an expiration date.

The Company has state net operating loss carryforwards at December 31, 2016 and 2015 of approximately $223.3 million and $213.9 million, respectively. These net operating loss carryforwards, if not used to offset future taxable income, will expire from 2031 to 2033. In addition, the Company has certain state tax credits which will begin to expire in 2026 if not utilized.

Income taxes receivable was $11.7 million and $6.5 million at December 31, 2016 and 2015, respectively, and was included in other current assets in the consolidated balance sheets. Income taxes payable of $0.5 million and $7.4 million at December 31, 2016 and 2015 was included in other accrued liabilities in the consolidated balance sheets.

The Company has recorded income taxes payable related to unrecognized tax benefits of $7.8 million and $5.4 million at December 31, 2016 and 2015, respectively, in other liabilities in the consolidated balance sheets. A reconciliation of the beginning and ending amount of unrecognized income tax benefits net of the federal benefit is as follows (in thousands):


	2016			2015			2014
Balance at January 1	$	4,511		$	2,923		$	1,893
Additions based on tax positions related to the current year		—			1,516			—
Additions for tax positions of prior years		5,427			2,874			1,030
Reductions as a result of the lapse of applicable statutes of limitations		(2,989	)		(2,802	)		—

Balance at December 31	$	6,949		$	4,511		$	2,923

The Company recognizes interest and penalties related to unrecognized tax benefits in its consolidated balance sheets. As of December 31, 2016 and 2015, the cumulative amounts recognized were $0.9 million and $1.0 million, respectively. It is possible the amount of unrecognized tax benefit could change in the next twelve months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, management does not anticipate the change will have a material impact on the Company’s consolidated financial statements.

The Company’s uncertain tax positions are related to tax years that remain subject to examination by the relevant taxing authorities. The Company and its subsidiaries file income tax returns in federal and in many state and local jurisdictions as well as foreign jurisdictions. The Company may be subject to examination by the Internal Revenue Service (“IRS”) for calendar year 2014 through 2015. Additionally, any net operating losses that were generated in prior years and utilized in these years may also be subject to examination by the IRS. In foreign jurisdictions, the Company may be subject to examination for calendar years 2012 through 2015. Generally, for state tax purposes, the Company’s 2011 through 2015 tax years remain open for examination by the tax authorities. At the date of this report there were no audits or inquires that had progressed sufficiently to predict their ultimate outcome.

One of the Company’s Puerto Rico subsidiaries was granted a tax exemption for which a tax credit of up to 15% of eligible payroll expenses is available to offset up to 50% of the income taxes attributed to that entity. The tax exemption will expire on December 31, 2017.

The Company does not provide for U.S. income taxes on the undistributed earnings of its foreign subsidiaries as it is the Company’s intention to utilize those earnings in the foreign operations for an indefinite period of time. At December 31, 2016, there were no undistributed earnings of the foreign subsidiaries. The amount of unrecognized deferred tax liability related to these temporary differences is not practicable at this time as this could be significantly impacted by the source location and amount of the distribution, the underlying tax rate already paid on the earnings, foreign withholding taxes, foreign currency translation adjustment and the opportunity to use foreign tax credits.

Derivatives	12 Months Ended
Derivatives	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	10. Derivatives The Company entered into foreign currency forward contracts during the years ended December 31, 2016 and 2015 in connection with (i) acquisitions in the U.K. and (ii) transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between US Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers. These foreign currency forward contracts did not meet the hedge accounting criteria under Accounting Standards Codification 815, Derivatives and Hedging. As such, changes in fair value resulted in gains of $0.5 million and losses of $1.9 million for the years ended December 31, 2016 and 2015, respectively which have been recorded in the consolidated statements of income. In May 2016, the Company entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £449.3 million. The senior notes effectively converted include $150.0 million aggregate principal amount of 6.125% Senior Notes, $300.0 million aggregate principal amount of 5.125% Senior Notes and $200.0 million aggregate principal amount of 5.625% Senior Notes. During the term of the swap agreements, the Company will receive semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company will make semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements result in £24.7 million of annual cash flows, from the Company’s U.K. business being converted to $35.8 million (at a 1.45 exchange rate). The interest rates applicable to the GBP interest payments are substantially the same as the interest rates in place for the existing USD-denominated debt. At maturity, the Company will repay the principal amounts listed above in GBP and receive the principal amount in USD. The Company has designated the cross currency swap agreements as qualifying hedging instruments and is accounting for these as net investment hedges. The fair value of the cross currency swap agreements of $73.1 million is recorded as an asset within derivative instruments on the consolidated balance sheets. The gains and losses resulting from fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive income as the swaps are effective in hedging the designated risk. Cash flows related to the cross currency swaps are included in operating activities in the consolidated statements of cash flows.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Fair Value Measurements

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

11. Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 9.0% and 9.5% Revenue Bonds, derivative instruments and contingent consideration liability as of December 31, 2016 and 2015 were as follows (in thousands):


	Carrying Amount				Fair Value
	December 31,				December 31,
	2016		2015		2016		2015
Amended and Restated Senior Credit Facility	$	1,799,993	$	1,135,861	$	1,799,993	$	1,135,861
6.125% Senior Notes due 2021	$	147,574	$	147,082	$	152,186	$	149,288
5.125% Senior Notes due 2022	$	295,442	$	294,749	$	293,595	$	275,590
5.625% Senior Notes due 2023	$	640,574	$	639,431	$	640,574	$	604,262
6.500% Senior Notes due 2024	$	381,268	$	—	$	389,847	$	—
9.0% and 9.5% Revenue Bonds	$	22,959	$	23,621	$	22,959	$	23,621
Derivative instruments	$	73,509	$	—	$	73,509	$	—
Contingent consideration liabilities	$	107	$	667	$	107	$	667

The Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes and 9.0% and 9.5% Revenue Bonds were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair values of the derivative instruments were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates.

The fair value of the contingent consideration liabilities were categorized as Level 3 in the GAAP fair value hierarchy. The contingent consideration liabilities were valued using a probability-weighted discounted cash flow method. This analysis reflected the contractual terms of the purchase agreements and utilized assumptions with regard to future earnings, probabilities of achieving such future earnings and a discount rate.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Leases

12 Months Ended

Dec. 31, 2016

Leases [Abstract]

Leases

12. Leases

The Company is obligated under certain operating leases to rent space for its facilities and other office space. The original terms of the leases typically range from five to ten years, with optional renewal periods.

Aggregate minimum lease payments under non-cancelable operating leases with original or remaining lease terms in excess of one year were as follows as of December 31, 2016 (in thousands):


2017	$	65,259
2018		58,564
2019		54,211
2020		49,870
2021		46,799
Thereafter		768,607

Total minimum rental obligations	$	1,043,310

During the years ended December 31, 2016, 2015 and 2014, rent expense was $73.3 million, $32.5 million and $12.2 million, respectively.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies The Company is, from time to time, subject to various claims and legal actions that arise in the ordinary course of the Company’s business, including claims for damages for personal injuries, medical malpractice, breach of contract, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In the opinion of management, the Company is not currently a party to any proceeding that would individually or in the aggregate have a material adverse effect on the Company’s business, financial condition or results of operations.

Noncontrolling Interests	12 Months Ended
Noncontrolling Interests	Dec. 31, 2016
Noncontrolling Interest [Abstract]
Noncontrolling Interests	14. Noncontrolling Interests On May 2, 2016, the Company opened Crestwyn Behavioral Health, a de novo inpatient psychiatric facility located in Memphis, Tennessee. The Company owns 60% of the equity interests in the entity that owns this facility, and two noncontrolling partners each own 20%. The value of the 40% noncontrolling interests is approximately $6.0 million and is based on the fair value of contributions. The Company consolidates the operations of the facility based on its 60% equity ownership and its control of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying consolidated balance sheets based on a put right that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control. On August 31, 2015, the Company completed the acquisition of a controlling interest in Southcoast, an inpatient psychiatric facility located in Fairhaven, Massachusetts. The Company owns 75% of the equity interests in the entity that owns this facility. The value of the 25% noncontrolling interest is approximately $9.2 million. The Company considered an income approach and other valuation methodologies to value the noncontrolling interests. The Company consolidates the operations of the facility based on its 75% equity ownership and its control of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying consolidated balance sheets based on a put right that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

Segment Information

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment Information

15. Segment Information

The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its facilities in the United States (the “U.S. Facilities”) and its facilities in the United Kingdom (the “U.K. Facilities”) separately to assess performance and make decisions, the Company’s operating segments include its U.S. Facilities and U.K. Facilities. At December 31, 2016, the U.S. Facilities included 208 behavioral healthcare facilities with approximately 8,500 beds in 39 states and Puerto Rico, and the U.K. Facilities included 365 behavioral healthcare facilities with approximately 8,600 beds in the U.K.

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands):


	Year Ended December 31,
	2016			2015			2014
Revenue:
U.S. Facilities	$	1,698,525		$	1,426,205		$	850,625
U.K. Facilities		1,110,361			360,698			151,127
Corporate and Other		2,028			7,589			2,849

	$	2,810,914		$	1,794,492		$	1,004,601

Segment EBITDA (1):
U.S. Facilities	$	443,341		$	377,587		$	209,668
U.K. Facilities		245,046			90,035			39,832
Corporate and Other		(79,797	)		(62,790	)		(34,012	)

	$	608,590		$	404,832		$	215,488


	Year Ended December 31,
	2016			2015			2014
Segment EBITDA (1)	$	608,590		$	404,832		$	215,488
Plus (less):
Equity-based compensation expense		(28,345	)		(20,472	)		(10,058	)
Debt extinguishment costs		(4,253	)		(10,818	)		—
Loss on divestiture		(178,809	)		—			—
Gain (loss) on foreign currency derivatives		523			(1,926	)		15,262
Transaction-related expenses		(48,323	)		(36,571	)		(13,650	)
Interest expense, net		(181,325	)		(106,742	)		(48,221	)
Depreciation and amortization		(135,103	)		(63,550	)		(32,667	)

Income from continuing operations before income taxes	$	32,955		$	164,753		$	126,154


	U.S. Facilities			U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2016	$	1,941,873		$	186,342		$	—	$	2,128,215
Increase from 2016 acquisitions		95,645			686,149			—		781,794
Foreign currency translation loss		—			(127,020	)		—		(127,020	)
Loss on divestiture		(85	)		(106,852	)		—		(106,937	)
Prior year purchase price adjustments		4,362			774			—		5,136

Balance at December 31, 2016	$	2,041,795		$	639,393		$	—	$	2,681,188


	December 31,
	2016		2015
Assets (2):
U.S. Facilities	$	3,382,167	$	3,061,519
U.K. Facilities		2,441,018		1,045,922
Corporate and Other		201,541		171,767

	$	6,024,726	$	4,279,208

(1)

Segment EBITDA is defined as income from continuing operations before provision for income taxes, equity-based compensation expense, debt extinguishment costs, gain on foreign currency derivatives, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(2)

Assets include property and equipment for the U.S. Facilities of $1.0 billion, U.K. Facilities of $1.7 billion and corporate and other of $27.1 million at December 31, 2016. Assets include property and equipment for the U.S. Facilities of $832.2 million, U.K. Facilities of $824.4 million and corporate and other of $52.4 million at December 31, 2015.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Employee Benefit Plans

12 Months Ended

Dec. 31, 2016

Compensation and Retirement Disclosure [Abstract]

Employee Benefit Plans

16. Employee Benefit Plans

Defined Contribution Plan

The Company maintains a qualified defined contribution 401(k) plan covering substantially all of its employees in the U.S. The Company may, at its discretion, make contributions to the plan. The Company contributed $0.1 million to the 401(k) plan for each of the years ended December 31, 2016, 2015 and 2014.

Partnerships in Care Pension Plan

As part of the acquisition of Partnerships in Care on July 1, 2014, the Company assumed a frozen contributory defined benefit retirement plan (“Partnerships in Care Pension Plan”) covering substantially all of the employees of Partnerships in Care and its subsidiaries prior to May 1, 2005 at which time, the Partnerships in Care Plan was frozen to new participants. Effective May 2015, the active participants no longer accrue benefits. The benefits under the Partnerships in Care Pension Plan were primarily based on years of service and final average earnings.

The Company accounts for the Partnerships in Care Pension Plan in accordance with ASC 715-30 “Compensation — Defined Benefit Plans”, (“ASC 715-30”). In accordance with ASC 715-30, the Company recognizes the unfunded liability of the Partnerships in Care Pension Plan on the Company’s consolidated balance sheet and unrecognized gains (losses) and prior service credits (costs) as changes in other comprehensive income (loss). The measurement date of the Partnerships in Care Pension Plan’s assets and liabilities coincides with the Company’s year-end. The Company’s pension benefit obligation is measured using actuarial calculations that incorporate discount rates, rate of compensation increases, when applicable, expected long-term returns on plan assets and consider expected age of retirement and mortality. Expected return on plan assets is determined by using the specific asset distribution at the measurement date.

The following table summarizes the funded status (unfunded liability) of the Partnerships in Care Pension Plan based upon actuarial valuations prepared as of December 31, 2016 and 2015 (in thousands):


	2016		2015
Projected benefit obligation	$	64,162	$	58,107
Fair value of plan assets		53,462		55,286

Unfunded liability	$	10,700	$	2,821

The following table summarizes changes in the Partnerships in Care Pension Plan net pension liability as of December 31, 2016 and 2015 (in thousands):


	2016			2015
Net pension liability at beginning of period	$	2,821		$	9,554
Employer contributions		(740	)		(1,217	)
Net pension expense (benefit)		339			(419	)
Pension liability adjustment		8,781			(4,661	)
Foreign currency translation loss		(501	)		(436	)

Net pension liability at end of period	$	10,700		$	2,821

A pension liability of $10.7 million and $2.8 million were recorded within other liabilities on the consolidated balance sheet as of December 31, 2016 and 2015. The following assumptions were used to determine the plan benefit obligation:


Discount rate	2.7	%	3.8	%
Compensation increase rate	2.4	%	2.2	%
Measurement date	December 31, 2016		December 31, 2015

A summary of the components of net pension plan expense for the year ended December 31, 2016 and 2015 is as follows (in thousands):


	2016			2015
Interest cost on projected benefit obligation	$	1,964		$	2,369
Service cost on projected benefit obligation		—			616
Curtailments on projected benefit obligation		—			(1,373	)
Expected return on assets		(1,625	)		(2,031	)

Total pension plan expense (benefit)	$	339		$	(419	)

Assumptions used to determine the net periodic pension plan expense for the year ended December 31, 2016 and 2015 were as follows:


	2016			2015
Discount rate		2.7	%		3.8	%
Expected long-term rate of return on plan assets		2.7	%		3.8	%

The Company recognizes changes in the funded status of the pension plan as a direct increase or decrease to stockholders’ equity through accumulated other comprehensive income. The accumulated other comprehensive income (loss) related to the Partnerships in Care Pension Plan for the years ended December 31, 2016, 2015 and 2014 was $(7.4) million ($(6.1) million net of taxes), $2.6 million ($1.7 million net of taxes) and $(2.8) million ($(2.2) million net of taxes), respectively.

The trustees of the Partnerships in Care Pension Plan are required to invest assets in the best interest of the Partnerships in Care Pension Plan’s members and also ensure liquid assets are available to make benefit payments as they become due. Performance of the Partnerships in Care Pension Plan’s assets are monitored quarterly, at a minimum, and asset allocations are adjusted as needed. The Partnerships in Care Pension Plan’s weighted-average asset allocations by asset category as of December 31, 2016 and 2015 were as follows:


	December 31, 2016			December 31, 2015
Cash and cash equivalents		1.5	%		1.7	%
U.K. government obligation		14.5	%		3.8	%
Annuity contracts		41.6	%		46.5	%
Equity securities		26.3	%		35.7	%
Debt securities		12.1	%		8.5	%
Other		4.0	%		3.8	%

As of December 31, 2016 and 2015, the Partnerships in Care Pension Plan cash and cash equivalents were classified as Level 1 in the GAAP fair value hierarchy. Fair values were based on utilizing quoted prices (unadjusted) in active markets for identical assets. The U.K. government obligations, annuity contracts, equity securities, debt securities and other investments were classified as Level 2 in the GAAP fair value hierarchy. Fair values were based on data points that are observable, such as quoted prices, interest rates and yield curves.

Other Comprehensive Loss

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Other Comprehensive Loss

17. Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):


	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments		Pension Plan			Total
Balance at January 1, 2014	$	—		$	—	$	—		$	—
Foreign currency translation loss		(66,206	)		—		—			(66,206	)
Pension liability adjustment, net of tax of $0.6 million		—			—		(2,164	)		(2,164	)

Balance at December 31, 2014		(66,206	)		—		(2,164	)		(68,370	)
Foreign currency translation loss		(40,103	)		—		—			(40,103	)
Pension liability adjustment, net of tax of $0.9 million		—			—		3,826			3,826

Balance at December 31, 2015		(106,309	)		—		1,662			(104,647	)
Foreign currency translation loss		(477,772	)		—		—			(477,772	)
Gain on derivative instruments, net of tax of $29.1 million		—			40,598		—			40,598
Pension liability adjustment, net of tax of $1.3 million		—			—		(7,749	)		(7,749	)

Balance at December 31, 2016	$	(584,081	)	$	40,598	$	(6,087	)	$	(549,570	)

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Quarterly Information (Unaudited)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Quarterly Information (Unaudited)

18. Quarterly Information (Unaudited)

The tables below present summarized unaudited quarterly results of operations for the years ended December 31, 2016 and 2015. Management believes that all necessary adjustments have been included in the amounts stated below for a fair presentation of the results of operations for the periods presented when read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2016 and 2015. Results of operations for a particular quarter are not necessarily indicative of results of operations for an annual period and are not predictive of future periods.


	Quarter Ended
	March 31,		June 30,		September 30,			December 31,
	(In thousands except per share amounts)
2016:
Revenue	$	616,813	$	756,548	$	734,665		$	702,888
Income from continuing operations before income taxes	$	32,479	$	73,852	$	(115,814	)(1)	$	42,438	(2)
Net income attributable to Acadia Healthcare Company, Inc. stockholders	$	25,688	$	56,445	$	(117,808	)(1)	$	41,818	(2)
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.31	$	0.65	$	(1.36	)(1)	$	0.48	(2)
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.31	$	0.65	$	(1.36	)(1)	$	0.48	(2)
2015:
Revenue	$	365,783	$	453,660	$	479,730		$	495,319
Income from continuing operations before income taxes	$	21,205	$	49,355	$	41,645	(3)	$	52,518
Net income attributable to Acadia Healthcare Company, Inc. stockholders	$	14,594	$	33,844	$	29,550	(3)	$	34,566
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.23	$	0.50	$	0.42	(3)	$	0.49
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.23	$	0.49	$	0.42	(3)	$	0.49

(1)	Includes loss on divestiture of $174.7 million and debt extinguishment costs of $3.4 million, or $142.0 million net of taxes, in connection with the U.K. Divestiture and the TLB repricing.

(2)	Includes loss on divestiture of $4.0 million and debt extinguishment costs of $0.8 million, or $3.1 million net of taxes, in connection with the Company’s divestitures and the Refinancing Amendment.

(3)

Includes debt extinguishment costs of $10.0 million, or $6.8 million net of taxes, in connection with the redemption of $88.3 million of the 12.875% Senior Notes on September 21, 2015. On November 1, 2015, the Company redeemed all of the outstanding $9.2 million principal amount of the 12.875% Senior Notes and incurred additional debt extinguishment cost of $0.8 million.

Financial Information for the Company and Its Subsidiaries

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Financial Information for the Company and Its Subsidiaries

19. Financial Information for the Company and Its Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% senior notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries as of December 31, 2016 and 2015, and for the years ended December 31, 2016, 2015 and 2014. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor subsidiaries and eliminations.

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2016

(In thousands)


	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	15,681	$	41,382	$	—		$	57,063
Accounts receivable, net		—		209,124		54,203		—			263,327
Other current assets		—		61,724		45,813		—			107,537

Total current assets		—		286,529		141,398		—			427,927
Property and equipment, net		—		940,880		1,762,815		—			2,703,695
Goodwill		—		1,935,260		745,928		—			2,681,188
Intangible assets, net		—		56,676		26,634		—			83,310
Deferred tax assets – noncurrent		13,522		—		4,606		(14,348	)		3,780
Derivative instruments		73,509		—		—		—			73,509
Investment in subsidiaries		4,885,865		—		—		(4,885,865	)		—
Other assets		493,294		40,480		7,189		(489,646	)		51,317

Total assets	$	5,466,190	$	3,259,825	$	2,688,570	$	(5,389,859	)	$	6,024,726

Current liabilities:
Current portion of long-term debt	$	34,550	$	—	$	255	$	—		$	34,805
Accounts payable		—		49,205		30,829		—			80,034
Accrued salaries and benefits		—		72,835		32,233		—			105,068
Other accrued liabilities		33,616		24,375		64,967		—			122,958

Total current liabilities		68,166		146,415		128,284		—			342,865
Long-term debt		3,230,300		—		512,350		(489,646	)		3,253,004
Deferred tax liabilities – noncurrent		—		40,574		52,294		(14,348	)		78,520
Other liabilities		—		101,938		62,921		—			164,859

Total liabilities		3,298,466		288,927		755,849		(503,994	)		3,839,248

Redeemable noncontrolling interests		—		—		17,754		—			17,754

Total equity		2,167,724		2,970,898		1,914,967		(4,885,865	)		2,167,724

Total liabilities and equity	$	5,466,190	$	3,259,825	$	2,688,570	$	(5,389,859	)	$	6,024,726

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2015

(In thousands)


	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	1,987	$	9,228	$	—		$	11,215
Accounts receivable, net		—		187,546		29,080		—			216,626
Other current assets		—		57,968		8,927		—			66,895

Total current assets		—		247,501		47,235		—			294,736
Property and equipment, net		—		805,439		903,614		—			1,709,053
Goodwill		—		1,835,339		292,876		—			2,128,215
Intangible assets, net		—		57,024		2,551		—			59,575
Deferred tax assets – noncurrent		3,946		40,587		4,581		—			49,114
Investment in subsidiaries		3,495,067		—		—		(3,495,067	)		—
Other assets		427,270		32,947		2,322		(424,024	)		38,515

Total assets	$	3,926,283	$	3,018,837	$	1,253,179	$	(3,919,091	)	$	4,279,208

Current liabilities:
Current portion of long-term debt	$	45,125	$	—	$	235	$	—		$	45,360
Accounts payable		—		75,015		16,326		—			91,341
Accrued salaries and benefits		—		66,249		14,447		—			80,696
Other accrued liabilities		26,132		10,886		35,788		—			72,806

Total current liabilities		71,257		152,150		66,796		—			290,203
Long-term debt		2,171,998		—		447,410		(424,024	)		2,195,384
Deferred tax liabilities – noncurrent		—		—		23,936		—			23,936
Other liabilities		—		75,159		3,443		—			78,602

Total liabilities		2,243,255		227,309		541,585		(424,024	)		2,588,125

Redeemable noncontrolling interests		—		—		8,055		—			8,055

Total equity		1,683,028		2,791,528		703,539		(3,495,067	)		1,683,028

Total liabilities and equity	$	3,926,283	$	3,018,837	$	1,253,179	$	(3,919,091	)	$	4,279,208

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Year Ended December 31, 2016

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	1,662,734		$	1,190,089		$	—		$	2,852,823
Provision for doubtful accounts		—			(38,349	)		(3,560	)		—			(41,909	)

Revenue		—			1,624,385			1,186,529			—			2,810,914
Salaries, wages and benefits		28,345			865,104			648,405			—			1,541,854
Professional fees		—			89,062			96,424			—			185,486
Supplies		—			76,246			41,179			—			117,425
Rents and leases		—			34,540			38,808			—			73,348
Other operating expenses		—			206,308			106,248			—			312,556
Depreciation and amortization		—			58,018			77,085			—			135,103
Interest expense, net		50,921			75,848			54,556			—			181,325
Debt extinguishment costs		4,253			—			—			—			4,253
Loss on divestiture		—			778			178,031			—			178,809
Gain on foreign currency derivatives		(523	)		—			—			—			(523	)
Transaction-related expenses		—			32,173			16,150			—			48,323

Total expenses		82,996			1,438,077			1,256,886			—			2,777,959
(Loss) income from continuing operations before income taxes		(82,996	)		186,308			(70,357	)		—			32,955
Equity in earnings of subsidiaries		65,560			—			—			(65,560	)		—
(Benefit from) provision for income taxes		(21,612	)		68,335			(17,944	)		—			28,779

Income (loss) from continuing operations		4,176			117,973			(52,413	)		(65,560	)		4,176
Income from discontinued operations, net of income taxes		—			—			—			—			—

Net income (loss)		4,176			117,973			(52,413	)		(65,560	)		4,176
Net loss attributable to noncontrolling interests		—			—			1,967			—			1,967

Net income attributable to Acadia Healthcare Company, Inc.	$	4,176		$	117,973		$	(50,446	)	$	(65,560	)	$	6,143

Other comprehensive income:
Foreign currency translation gain		—			—			(477,772	)		—			(477,772	)
Gain on derivative instruments		40,598			—			—			—			40,598
Pension liability adjustment, net		—			—			(7,749	)		—			(7,749	)

Other comprehensive income		40,598			—			(485,521	)		—			(444,923	)

Comprehensive income (loss)	$	44,774		$	117,973		$	(535,967	)	$	(65,560	)	$	(438,780	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Year Ended December 31, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	1,415,016		$	414,603		$	—		$	1,829,619
Provision for doubtful accounts		—			(32,614	)		(2,513	)		—			(35,127	)

Revenue		—			1,382,402			412,090			—			1,794,492
Salaries, wages and benefits		20,472			726,215			227,045			—			973,732
Professional fees		—			83,422			33,041			—			116,463
Supplies		—			65,077			15,586			—			80,663
Rents and leases		—			29,094			3,434			—			32,528
Other operating expenses		—			170,018			36,728			—			206,746
Depreciation and amortization		—			41,768			21,782			—			63,550
Interest expense, net		68,533			17,476			20,733			—			106,742
Debt extinguishment costs		10,818			—			—			—			10,818
Loss on foreign currency derivatives		1,926			—			—			—			1,926
Transaction-related expenses		—			24,914			11,657			—			36,571

Total expenses		101,749			1,157,984			370,006			—			1,629,739
(Loss) income from continuing operations before income taxes		(101,749	)		224,418			42,084			—			164,753
Equity in earnings of subsidiaries		176,178			—			—			(176,178	)		—
(Benefit from) provision for income taxes		(37,047	)		85,765			4,670			—			53,388

Income (loss) from continuing operations		111,476			138,653			37,414			(176,178	)		111,365
Income from discontinued operations, net of income taxes		—			111			—			—			111

Net income (loss)		111,476			138,764			37,414			(176,178	)		111,476
Net loss attributable to noncontrolling interests		—			—			1,078			—			1,078

Net income attributable to Acadia Healthcare Company, Inc.	$	111,476		$	138,764		$	38,492		$	(176,178	)	$	112,554

Other comprehensive income:
Foreign currency translation gain		—			—			(40,103	)		—			(40,103	)
Pension liability adjustment, net		—			—			3,826			—			3,826

Other comprehensive income		—			—			(36,277	)		—			(36,277	)

Comprehensive income (loss)	$	111,476		$	138,764		$	2,215		$	(176,178	)	$	76,277

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Year Ended December 31, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	826,465		$	204,319		$	—		$	1,030,784
Provision for doubtful accounts		—			(23,866	)		(2,317	)		—			(26,183	)

Revenue		—			802,599			202,002			—			1,004,601
Salaries, wages and benefits		10,058			459,297			106,057			—			575,412
Professional fees		—			38,632			13,850			—			52,482
Supplies		—			40,511			7,911			—			48,422
Rents and leases		—			10,136			2,065			—			12,201
Other operating expenses		—			83,835			26,819			—			110,654
Depreciation and amortization		—			22,990			9,677			—			32,667
Interest expense, net		27,199			6,207			14,815			—			48,221
Gain on foreign currency derivatives		(15,262	)		—			—			—			(15,262	)
Transaction-related expenses		—			12,367			1,283			—			13,650

Total expenses		21,995			673,975			182,477			—			878,447
(Loss) income from continuing operations before income taxes		(21,995	)		128,624			19,525			—			126,154
Equity in earnings of subsidiaries		97,414			—			—			(97,414	)		—
(Benefit from) provision for income taxes		(7,621	)		44,608			5,935			—			42,922

Income (loss) from continuing operations		83,040			84,016			13,590			(97,414	)		83,232
Loss from discontinued operations, net of income taxes		—			(192	)		—			—			(192	)

Net income (loss)	$	83,040		$	83,824		$	13,590		$	(97,414	)	$	83,040

Other comprehensive loss:
Foreign currency translation loss		—			—			(66,206	)		—			(66,206	)
Pension liability adjustment, net		—			—			(2,164	)		—			(2,164	)

Other comprehensive loss		—			—			(68,370	)		—			(68,370	)

Comprehensive income (loss)	$	83,040		$	83,824		$	(54,780	)	$	(97,414	)	$	14,670

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2016

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	4,176		$	117,973		$	(52,413	)	$	(65,560	)	$	4,176
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(65,560	)		—			—			65,560			—
Depreciation and amortization		—			58,018			77,085			—			135,103
Amortization of debt issuance costs		10,751			—			(427	)		—			10,324
Equity-based compensation expense		28,345			—			—			—			28,345
Deferred income tax (benefit) expense		(2,172	)		50,611			(19,792	)		—			28,647
Loss from discontinued operations, net of taxes		—			—			—			—			—
Debt extinguishment costs		4,253			—			—			—			4,253
Loss on divestiture		—			778			178,031			—			178,809
(Gain) loss on foreign currency derivatives		(523	)		—			—			—			(523	)
Other		—			4,022			693			—			4,715
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(24,017	)		8,299			—			(15,718	)
Other current assets		—			(3,138	)		(17,510	)		—			(20,648	)
Other assets		(3,109	)		(4,048	)		(306	)		3,109			(4,354	)
Accounts payable and other accrued liabilities		—			(45,552	)		68,245			—			22,693
Accrued salaries and benefits		—			3,844			(12,416	)		—			(8,572	)
Other liabilities		—			4,050			434			—			4,484

Net cash (used in) provided by continuing operating activities		(23,839	)		162,541			229,923			3,109			371,734
Net cash used in discontinued operating activities		—			(10,256	)		—			—			(10,256	)

Net cash (used in) provided by operating activities		(23,839	)		152,285			229,923			3,109			361,478
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(103,359	)		(580,096	)		—			(683,455	)
Cash paid for capital expenditures		—			(177,593	)		(129,879	)		—			(307,472	)
Cash paid for real estate acquisitions		—			(28,956	)		(11,801	)		—			(40,757	)
Settlement of foreign currency derivatives		—			523			—			—			523
Cash received for divestiture		370,000			7,859			(4,593	)		—			373,266
Other		—			(1,573	)		(897	)		—			(2,470	)

Net cash used in investing activities		370,000			(303,099	)		(727,266	)		—			(660,365	)
Financing activities:
Borrowings on long-term debt		1,480,000			—			—			—			1,480,000
Borrowings on revolving credit facility		179,000			—			—			—			179,000
Principal payments on revolving credit facility		(337,000	)		—			—			—			(337,000	)
Principal payments on long-term debt		(49,706	)		(293,000	)		(3,344	)		296,109			(49,941	)
Repayment of assumed debt		(1,348,389	)		—			—			—			(1,348,389	)
Repayment of long-term debt		(200,594	)		—			—			—			(200,594	)
Payment of debt issuance costs		(36,649	)		—			—			—			(36,649	)
Issuance of common stock		685,097			—			—			—			685,097
Common stock withheld for minimum statutory taxes, net		(8,846	)		—			—			—			(8,846	)
Excess tax benefit from equity awards		—			—			—			—			—
Other		(1,149	)		(2,688	)		—			—			(3,837	)
Cash (used in) provided by intercompany activity		(707,925	)		460,196			546,947			(299,218	)		—

Net cash provided by (used in) financing activities		(346,161	)		164,508			543,603			(3,109	)		358,841

Effect of exchange rate changes on cash		—			—			(14,106	)		—			(14,106	)

Net increase in cash and cash equivalents		—			13,694			32,154			—			45,848
Cash and cash equivalents at beginning of the period		—			1,987			9,228			—			11,215

Cash and cash equivalents at end of the period	$	—		$	15,681		$	41,382		$	—		$	57,063

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	111,476		$	138,764		$	37,414		$	(176,178	)	$	111,476
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(176,178	)		—			—			176,178			—
Depreciation and amortization		—			41,768			21,782			—			63,550
Amortization of debt issuance costs		7,147			—			(438	)		—			6,709
Equity-based compensation expense		20,472			—			—			—			20,472
Deferred income tax (benefit) expense		617			42,246			750			—			43,613
Loss from discontinued operations, net of taxes		—			(111	)		—			—			(111	)
Debt extinguishment costs		10,818			—			—			—			10,818
Loss (gain) on foreign currency derivatives		1,926			—			—			—			1,926
Other		—			1,582			33			—			1,615
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(18,632	)		(6,322	)		—			(24,954	)
Other current assets		—			(1,152	)		(1,565	)		—			(2,717	)
Other assets		(1,100	)		(8,567	)		546			1,100			(8,021	)
Accounts payable and other accrued liabilities		—			(7,583	)		14,451			—			6,868
Accrued salaries and benefits		—			312			1,346			—			1,658
Other liabilities		—			9,350			(114	)		—			9,236

Net cash (used in) provided by continuing operating activities		(24,822	)		197,977			67,883			1,100			242,138
Net cash provided by discontinued operating activities		—			(1,735	)		—			—			(1,735	)

Net cash (used in) provided by operating activities		(24,822	)		196,242			67,883			1,100			240,403
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(254,848	)		(319,929	)		—			(574,777	)
Cash paid for capital expenditures		—			(172,329	)		(103,718	)		—			(276,047	)
Cash paid for real estate acquisitions		—			(25,293	)		(1,329	)		—			(26,622	)
Settlement of foreign currency derivatives		—			(1,926	)		—			—			(1,926	)
Other		—			(5,099	)		—			—			(5,099	)

Net cash used in investing activities		—			(459,495	)		(424,976	)		—			(884,471	)
Financing activities:
Borrowings on long-term debt		1,150,000			—			—			—			1,150,000
Borrowings on revolving credit facility		468,000			—			—			—			468,000
Principal payments on revolving credit facility		(310,000	)		—			—			—			(310,000	)
Principal payments on long-term debt		(31,965	)		—			(1,315	)		1,315			(31,965	)
Repayment of assumed CRC debt		(904,467	)		—			—			—			(904,467	)
Repayments of senior notes		(97,500	)		—			—			—			(97,500	)
Payment of debt issuance costs		(26,421	)		—			—			—			(26,421	)
Payment of premium on senior notes		(7,480	)		—			—			—			(7,480	)
Issuance of Common Stock		331,308			—			—			—			331,308
Common stock withheld for minimum statutory taxes, net		(7,762	)		—			—			—			(7,762	)
Excess tax benefit from equity awards		309			—			—			—			309
Other		—			(420	)		—			—			(420	)
Cash provided by (used in) intercompany activity		(539,200	)		191,334			350,281			(2,415	)		—

Net cash provided by (used in) financing activities		24,822			190,914			348,966			(1,100	)		563,602

Effect of exchange rate changes on cash		—			(2,359	)		—			—			(2,359	)

Net (decrease) increase in cash and cash equivalents		—			(74,698	)		(8,127	)		—			(82,825	)
Cash and cash equivalents at beginning of the period		—			76,685			17,355			—			94,040

Cash and cash equivalents at end of the period	$	—		$	1,987		$	9,228		$	—		$	11,215

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	83,040		$	83,824		$	13,590		$	(97,414	)	$	83,040
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(97,414	)		—			—			97,414			—
Depreciation and amortization		—			22,990			9,677			—			32,667
Amortization of debt issuance costs		2,748			—			450			—			3,198
Equity-based compensation expense		10,058			—			—			—			10,058
Deferred income tax (benefit) expense		(1,969	)		5,231			3,953			—			7,215
Loss from discontinued operations, net of taxes		—			192			—			—			192
Gain on foreign currency derivatives		(15,262	)		—			—			—			(15,262	)
Other		—			449			39			—			488
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(13,636	)		(1,474	)		—			(15,110	)
Other current assets		—			(2,205	)		194			—			(2,011	)
Other assets		(1,151	)		(6,910	)		397			1,151			(6,513	)
Accounts payable and other accrued liabilities		—			(5,559	)		8,352			—			2,793
Accrued salaries and benefits		—			11,035			945			—			11,980
Other liabilities		—			1,769			980			—			2,749

Net cash (used in) provided by continuing operating activities		(19,950	)		97,180			37,103			1,151			115,484
Net cash used in discontinued operating activities		—			(198	)		—			—			(198	)

Net cash (used in) provided by operating activities		(19,950	)		96,982			37,103			1,151			115,286
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(723,064	)		(15,638	)		—			(738,702	)
Cash paid for capital expenditures		—			(83,864	)		(29,380	)		—			(113,244	)
Cash paid for real estate acquisitions		—			(23,177	)		—			—			(23,177	)
Settlement of foreign currency derivatives		15,262			—			—			—			15,262
Other		—			(913	)		—			—			(913	)

Net cash used in investing activities		15,262			(831,018	)		(45,018	)		—			(860,774	)
Financing activities:
Borrowings on long-term debt		542,500			—			—			—			542,500
Borrowings on revolving credit facility		230,500			—			—			—			230,500
Principal payments on revolving credit facility		(284,000	)		—			—			—			(284,000	)
Principal payments on long-term debt		(7,500	)		—			(1,346	)		1,151			(7,695	)
Payment of debt issuance costs		(12,993	)		—			—			—			(12,993	)
Issuance of common stock, net		374,431			—			—			—			374,431
Common stock withheld for minimum statutory taxes, net		(4,099	)		—			—			—			(4,099	)
Excess tax benefit from equity awards		4,617			—			—			—			4,617
Cash paid for contingent consideration		—			(5,000	)		—			—			(5,000	)
Other		—			(289	)		—			—			(289	)
Cash (used in) provided by intercompany activity		(838,768	)		816,010			23,135			(377	)		—

Net cash provided by financing activities		4,688			810,721			21,789			774			837,972

Effect of exchange rate changes on cash		—			—			(3,013	)		—			(3,013	)

Net increase in cash and cash equivalents		—			76,685			10,861			1,925			89,471
Cash and cash equivalents at beginning of the period		—			—			6,494			(1,925	)		4,569

Cash and cash equivalents at end of the period	$	—		$	76,685		$	17,355		$	—		$	94,040

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Cash and Cash Equivalents

Cash and Cash Equivalents

Revenue and Accounts Receivable

Revenue and Accounts Receivable

The following table presents the percentage of revenue before provision for doubtful accounts generated by each payor type:


	Year Ended December 31,
	2016			2015			2014
Commercial		18.7	%		23.1	%		23.0	%
Medicare		9.4			11.7			19.4
Medicaid		25.4			33.3			38.3
U.K. public funded sources		35.8			19.5			14.5
Self-Pay		9.4			9.6			2.5
Other		1.3			2.8			2.3

Revenue before provision for doubtful accounts		100	%		100	%		100	%

Allowance for Contractual Discounts

Allowance for Contractual Discounts

Allowance for Doubtful Accounts

Allowance for Doubtful Accounts

A summary of activity in the Company’s allowance for doubtful accounts is as follows (in thousands):


	Balance at Beginning of Period		Additions Charged to Costs and Expenses		Accounts Written Off, Net of Recoveries			Balance at End of Period
Year ended December 31, 2014	$	18,345	$	26,183	$	(22,079	)	$	22,449
Year ended December 31, 2015		22,449		35,127		(28,244	)		29,332
Year ended December 31, 2016		29,332		41,909		(32,325	)		38,916

Charity Care

Charity Care

Insurance

Insurance

Property and Equipment and Other Long-Lived Assets

Property and Equipment and Other Long-Lived Assets

Goodwill and Indefinite-Lived Intangible Assets

Goodwill and Indefinite-Lived Intangible Assets

Other Current Assets

Other Current Assets

Other current assets consisted of the following (in thousands):


	As of December 31,
	2016		2015
Other receivables	$	44,975	$	17,518
Prepaid expenses		27,455		21,817
Income taxes receivable		11,714		6,540
Workers’ compensation deposits – current portion		10,000		7,500
Insurance receivable – current portion		6,472		5,290
Inventory		4,633		4,681
Other		2,288		3,549

Other current assets	$	107,537	$	66,895

Other Accrued Liabilities

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):


	As of December 31,
	2016		2015
Accrued expenses	$	37,323	$	17,921
Accrued interest		33,616		26,132
Unearned income		28,805		446
Insurance liability – current portion		11,672		10,490
Accrued property taxes		2,732		2,951
Other		8,283		7,499
Income taxes payable		527		7,367

Other accrued liabilities	$	122,958	$	72,806

Stock Compensation

Stock Compensation

Earnings Per Share

Earnings Per Share

Income Taxes

Income Taxes

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Step 1: Identify the contract with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Percentage of Revenue before Provision for Doubtful Accounts Generated by Each Payor Type

The following table presents the percentage of revenue before provision for doubtful accounts generated by each payor type:


	Year Ended December 31,
	2016			2015			2014
Commercial		18.7	%		23.1	%		23.0	%
Medicare		9.4			11.7			19.4
Medicaid		25.4			33.3			38.3
U.K. public funded sources		35.8			19.5			14.5
Self-Pay		9.4			9.6			2.5
Other		1.3			2.8			2.3

Revenue before provision for doubtful accounts		100	%		100	%		100	%

Summary of Activity in the Company's Allowance for Doubtful Accounts

A summary of activity in the Company’s allowance for doubtful accounts is as follows (in thousands):


	Balance at Beginning of Period		Additions Charged to Costs and Expenses		Accounts Written Off, Net of Recoveries			Balance at End of Period
Year ended December 31, 2014	$	18,345	$	26,183	$	(22,079	)	$	22,449
Year ended December 31, 2015		22,449		35,127		(28,244	)		29,332
Year ended December 31, 2016		29,332		41,909		(32,325	)		38,916

Other Current Assets

Other current assets consisted of the following (in thousands):


	As of December 31,
	2016		2015
Other receivables	$	44,975	$	17,518
Prepaid expenses		27,455		21,817
Income taxes receivable		11,714		6,540
Workers’ compensation deposits – current portion		10,000		7,500
Insurance receivable – current portion		6,472		5,290
Inventory		4,633		4,681
Other		2,288		3,549

Other current assets	$	107,537	$	66,895

Summary of Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):


	As of December 31,
	2016		2015
Accrued expenses	$	37,323	$	17,921
Accrued interest		33,616		26,132
Unearned income		28,805		446
Insurance liability – current portion		11,672		10,490
Accrued property taxes		2,732		2,951
Other		8,283		7,499
Income taxes payable		527		7,367

Other accrued liabilities	$	122,958	$	72,806

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings (Loss) Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2016, 2015 and 2014 (in thousands except per share amounts):


	Year Ended December 31,
	2016		2015		2014
Numerator:
Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	6,143	$	112,443	$	83,232
Income (loss) from discontinued operation		—		111		(192	)

Net income attributable to Acadia Healthcare Company, Inc.	$	6,143	$	112,554	$	83,040

Denominator:
Weighted average shares outstanding for basic earnings per share		85,701		68,085		55,063
Effects of dilutive instruments		271		306		264

Shares used in computing diluted earnings per common share		85,972		68,391		55,327

Basic earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	0.07	$	1.65	$	1.51
Income (loss) from discontinued operations		—		—		—

Net income attributable to Acadia Healthcare Company, Inc.:	$	0.07	$	1.65	$	1.51

Diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$	0.07	$	1.64	$	1.50
Income (loss) from discontinued operations		—		—		—

Net income attributable to Acadia Healthcare Company, Inc.:	$	0.07	$	1.64	$	1.50

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2016

Transaction-related expenses comprised the following costs for the years ended December 31, 2016, 2015 and 2014 (in thousands):


	Year Ended December 31,
	2016		2015		2014
Legal, accounting and other fees	$	21,058	$	17,768	$	12,836
Advisory and financing commitment fees		14,850		10,337		—
Severance and contract termination costs		12,415		8,466		814

	$	48,323	$	36,571	$	13,650

Pro Forma Financial Information for Acquisitions


	Year Ended December 31,
	2016		2015
Revenue	$	2,765,221	$	2,715,749

Income from continuing operations, before income taxes	$	173,707	$	113,297

CRC Health Group Inc And Other Acquisitions [Member]

Preliminary Fair Values of Assets Acquired and Liabilities Assumed at Corresponding Acquisition Date


	Priory		Other		Total
Cash	$	10,253	$	2,488	$	12,741
Accounts receivable		57,832		4,289		62,121
Prepaid expenses and other current assets		7,921		143		8,064
Property and equipment		1,598,156		35,400		1,633,556
Goodwill		686,149		95,645		781,794
Intangible assets		23,200		338		23,538
Other assets		7,760		47		7,807

Total assets acquired		2,391,271		138,350		2,529,621
Accounts payable		24,203		805		25,008
Accrued salaries and benefits		39,588		797		40,385
Other accrued expenses		48,305		390		48,695
Deferred tax liabilities – noncurrent		59,972		269		60,241
Debt		1,348,389		—		1,348,389
Other liabilities		63,583		30,242		93,825

Total liabilities assumed		1,584,040		32,503		1,616,543

Net assets acquired	$	807,231	$	105,847	$	913,078

Priory [Member]

Preliminary Fair Values of Assets Acquired and Liabilities Assumed at Corresponding Acquisition Date

The fair values of assets acquired and liabilities assumed during 2015, at the corresponding acquisition dates, were as follows (in thousands):


	CRC		Other		Total
Cash	$	19,599	$	5,334	$	24,933
Accounts receivable		47,035		20,445		67,480
Prepaid expenses and other current assets		26,945		2,555		29,500
Property and equipment		136,163		273,143		409,306
Goodwill		1,039,320		322,017		1,361,337
Intangible assets		37,000		204		37,204
Deferred tax asset-noncurrent		78,664		—		78,664
Other assets		6,478		51		6,529

Total assets acquired		1,391,204		623,749		2,014,953
Accounts payable		4,741		4,961		9,702
Accrued salaries and benefits		14,827		3,200		18,027
Other accrued expenses		38,873		5,782		44,655
Deferred tax liabilities – noncurrent		—		13,541		13,541
Debt		904,467		—		904,467
Other liabilities		34,720		10		34,730

Total liabilities assumed		997,628		27,494		1,025,122

Redeemable noncontrolling interests		—		9,132		9,132

Net assets acquired	$	393,576	$	587,123	$	980,699

Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following as of December 31, 2016 and 2015 (in thousands):


	Gross Carrying Amount				Accumulated Amortization
	December 31, 2016		December 31, 2015		December 31, 2016			December 31, 2015
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(1,750	)
Non-compete agreements		1,147		1,247		(1,147	)		(1,247	)

		3,247		3,347		(3,247	)		(2,997	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,228		11,479		—			—
Trade names		57,538		37,800		—			—
Certificates of need		13,544		9,946		—			—

		83,310		59,225		—			—

Total	$	86,557	$	62,572	$	(3,247	)	$	(2,997	)

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):


	December 31, 2016			December 31, 2015
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans	$	400,000		$	500,750
Senior Secured Term B Loans		1,435,450			495,000
Senior Secured Revolving Line of Credit		—			158,000
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			—
9.0% and 9.5% Revenue Bonds		22,175			22,410
Less: unamortized debt issuance costs, discount and premium		(59,816	)		(35,416	)

		3,287,809			2,240,744
Less: current portion		(34,805	)		(45,360	)

Long-term debt	$	3,253,004		$	2,195,384

Summary of Aggregate Maturities of Long-Term Debt

The aggregate maturities of long-term debt as of December 31, 2016 were as follows (in thousands):


2017	$	34,805
2018		34,830
2019		34,855
2020		44,880
2021		474,910
Thereafter		2,723,345

Total	$	3,347,625

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Equity-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Activity

Stock option activity during 2015 and 2016 was as follows (aggregate intrinsic value in thousands):


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2015		737,422		$	32.19		8.09	$	14,512
Options granted		204,700			63.07		9.21		1,724
Options exercised		(214,079	)		42.75		N/A		9,890
Options cancelled		(33,300	)		46.53		N/A		N/A

Options outstanding at December 31, 2015		694,743			42.87		7.70		20,717
Options granted		503,850			57.98		9.28		297
Options exercised		(57,397	)		31.92		N/A		1,530
Options cancelled		(140,250	)		57.13		N/A		N/A

Options outstanding at December 31, 2016		1,000,946		$	49.42		7.80	$	8,166

Options exercisable at December 31, 2015		106,330		$	36.41		5.83	$	4,968

Restricted Stock Activity

Restricted stock activity during 2015 and 2016 was as follows:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2015		722,028		$	39.77
Granted		503,052			62.67
Cancelled		(44,900	)		49.55
Vested		(235,618	)		34.93

Unvested at December 31, 2015		944,562		$	52.74
Granted		387,347			55.38
Cancelled		(122,178	)		57.02
Vested		(365,312	)		47.18

Unvested at December 31, 2016		844,419		$	55.76

Restricted Stock Unit Activity

Restricted stock unit activity during 2015 and 2016 was as follows:


	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2015		125,113		$	38.73
Granted		217,994			61.77
Cancelled		—			—
Vested		(125,023	)		32.38

Unvested at December 31, 2015		218,084		$	56.97
Granted		230,750			56.95
Cancelled		—			—
Vested		(175,235	)		52.71

Unvested at December 31, 2016		273,599		$	59.68

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2016 and 2015:


	December 31, 2016			December 31, 2015
Weighted average grant-date fair value of options	$	18.96		$	21.78
Risk-free interest rate		1.4	%		1.5	%
Expected volatility		33	%		35	%
Expected life (in years)		5.5			5.5

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Components of Provision for Income Taxes

Income tax expense (benefit) from continuing operations consists of the following for the periods presented (in thousands):


	Year Ended December 31,
	2016			2015			2014
Current:
Federal	$	572		$	(218	)	$	30,834
State		(863	)		4,078			3,959
Foreign		423			5,915			914

Total current		132			9,775			35,707
Deferred:
Federal		45,077			40,635			2,667
State		1,491			5,349			353
Foreign		(17,921	)		(2,371	)		4,195

Total deferred provision		28,647			43,613			7,215

Provision for (benefit from) income taxes	$	28,779		$	53,388		$	42,922

Effective Income Tax Rate

A reconciliation of the U.S. federal statutory rate, from continuing operations, to the effective tax rate is as follows for the periods presented:


	Year Ended December 31,
	2016			2015			2014
U.S. federal statutory rate on income before income taxes		35.0	%		35.0	%		35.0	%
Impact of foreign operations		(13.5	)		(10.0	)		(4.2	)
Impact of foreign divestiture		39.2			—			—
Effects of statutory rate change		(14.5	)		—			—
State income taxes, net of federal tax effect		7.5			4.8			2.3
Permanent differences		8.3			4.2			1.1
Transaction related items		25.9			—			—
Change in valuation allowance		2.8			1.2			(0.1	)
Unrecognized tax benefit release		(7.2	)		—			—
Other		3.8			(2.8	)		(0.1	)

Effective income tax rate		87.3	%		32.4	%		34.0	%

Deferred Tax Assets and Liabilities


	December 31,
	2016			2015
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	37,638		$	47,695
Bad debt allowance		15,381			14,050
Accrued compensation and severance		23,379			20,150
Pension reserves		697			536
Insurance reserves		17,468			15,449
Leases		2,926			2,675
Accrued expenses		—			5,324
Other assets		2,038			3,551

Total gross deferred tax assets		99,527			109,430
Less: valuation allowance		(16,031	)		(16,571	)

Deferred tax assets		83,496			92,859
Deferred tax liabilities:
Fixed asset basis difference		(45,510	)		(11,392	)
Prepaid items		(1,324	)		(3,113	)
Intangible assets		(77,655	)		(48,918	)
Accrued expenses		(4,531	)		—
Other liabilities		(29,216	)		(4,258	)

Total deferred tax liabilities		(158,236	)		(67,681	)

Total net deferred tax asset (liability)	$	(74,740	)	$	25,178

Unrecognized Income Tax Benefits Net of Federal Benefit

A reconciliation of the beginning and ending amount of unrecognized income tax benefits net of the federal benefit is as follows (in thousands):


	2016			2015			2014
Balance at January 1	$	4,511		$	2,923		$	1,893
Additions based on tax positions related to the current year		—			1,516			—
Additions for tax positions of prior years		5,427			2,874			1,030
Reductions as a result of the lapse of applicable statutes of limitations		(2,989	)		(2,802	)		—

Balance at December 31	$	6,949		$	4,511		$	2,923

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liability


	Carrying Amount				Fair Value
	December 31,				December 31,
	2016		2015		2016		2015
Amended and Restated Senior Credit Facility	$	1,799,993	$	1,135,861	$	1,799,993	$	1,135,861
6.125% Senior Notes due 2021	$	147,574	$	147,082	$	152,186	$	149,288
5.125% Senior Notes due 2022	$	295,442	$	294,749	$	293,595	$	275,590
5.625% Senior Notes due 2023	$	640,574	$	639,431	$	640,574	$	604,262
6.500% Senior Notes due 2024	$	381,268	$	—	$	389,847	$	—
9.0% and 9.5% Revenue Bonds	$	22,959	$	23,621	$	22,959	$	23,621
Derivative instruments	$	73,509	$	—	$	73,509	$	—
Contingent consideration liabilities	$	107	$	667	$	107	$	667

Leases (Tables)

12 Months Ended

Dec. 31, 2016

Leases [Abstract]

Schedule of Aggregate Minimum Lease Payments under Non-cancelable Operating Leases

Aggregate minimum lease payments under non-cancelable operating leases with original or remaining lease terms in excess of one year were as follows as of December 31, 2016 (in thousands):


2017	$	65,259
2018		58,564
2019		54,211
2020		49,870
2021		46,799
Thereafter		768,607

Total minimum rental obligations	$	1,043,310

Segment Information (Tables)

12 Months Ended

Dec. 31, 2016

Summary of Reconciliation of Segment EBITDA to Income from Continuing Operations

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands):


	Year Ended December 31,
	2016			2015			2014
Revenue:
U.S. Facilities	$	1,698,525		$	1,426,205		$	850,625
U.K. Facilities		1,110,361			360,698			151,127
Corporate and Other		2,028			7,589			2,849

	$	2,810,914		$	1,794,492		$	1,004,601

Segment EBITDA (1):
U.S. Facilities	$	443,341		$	377,587		$	209,668
U.K. Facilities		245,046			90,035			39,832
Corporate and Other		(79,797	)		(62,790	)		(34,012	)

	$	608,590		$	404,832		$	215,488


	Year Ended December 31,
	2016			2015			2014
Segment EBITDA (1)	$	608,590		$	404,832		$	215,488
Plus (less):
Equity-based compensation expense		(28,345	)		(20,472	)		(10,058	)
Debt extinguishment costs		(4,253	)		(10,818	)		—
Loss on divestiture		(178,809	)		—			—
Gain (loss) on foreign currency derivatives		523			(1,926	)		15,262
Transaction-related expenses		(48,323	)		(36,571	)		(13,650	)
Interest expense, net		(181,325	)		(106,742	)		(48,221	)
Depreciation and amortization		(135,103	)		(63,550	)		(32,667	)

Income from continuing operations before income taxes	$	32,955		$	164,753		$	126,154

Summary of Assets by Operating Segment


	December 31,
	2016		2015
Assets (2):
U.S. Facilities	$	3,382,167	$	3,061,519
U.K. Facilities		2,441,018		1,045,922
Corporate and Other		201,541		171,767

	$	6,024,726	$	4,279,208

(1)

(2)

Goodwill [Member]

Summary of Assets by Operating Segment


	U.S. Facilities			U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2016	$	1,941,873		$	186,342		$	—	$	2,128,215
Increase from 2016 acquisitions		95,645			686,149			—		781,794
Foreign currency translation loss		—			(127,020	)		—		(127,020	)
Loss on divestiture		(85	)		(106,852	)		—		(106,937	)
Prior year purchase price adjustments		4,362			774			—		5,136

Balance at December 31, 2016	$	2,041,795		$	639,393		$	—	$	2,681,188

Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2016

Compensation and Retirement Disclosure [Abstract]

Summary of Funded Status (Unfunded Liability) of Partnerships in Care Pension Plan Based Upon Actuarial Valuations


	2016		2015
Projected benefit obligation	$	64,162	$	58,107
Fair value of plan assets		53,462		55,286

Unfunded liability	$	10,700	$	2,821

Summary of Changes in Partnerships in Care Pension Plan Net Pension Liability

The following table summarizes changes in the Partnerships in Care Pension Plan net pension liability as of December 31, 2016 and 2015 (in thousands):


	2016			2015
Net pension liability at beginning of period	$	2,821		$	9,554
Employer contributions		(740	)		(1,217	)
Net pension expense (benefit)		339			(419	)
Pension liability adjustment		8,781			(4,661	)
Foreign currency translation loss		(501	)		(436	)

Net pension liability at end of period	$	10,700		$	2,821

Summary of Assumptions Used to Determine Plan Benefit obligation


Discount rate	2.7	%	3.8	%
Compensation increase rate	2.4	%	2.2	%
Measurement date	December 31, 2016		December 31, 2015

Assumptions used to determine the net periodic pension plan expense for the year ended December 31, 2016 and 2015 were as follows:


	2016			2015
Discount rate		2.7	%		3.8	%
Expected long-term rate of return on plan assets		2.7	%		3.8	%

Summary of Components of Net Pension Plan Expense

A summary of the components of net pension plan expense for the year ended December 31, 2016 and 2015 is as follows (in thousands):


	2016			2015
Interest cost on projected benefit obligation	$	1,964		$	2,369
Service cost on projected benefit obligation		—			616
Curtailments on projected benefit obligation		—			(1,373	)
Expected return on assets		(1,625	)		(2,031	)

Total pension plan expense (benefit)	$	339		$	(419	)

Schedule of Weighted-Average Asset Allocation by Asset Category in Partnerships in Care Pension Plan

The Partnerships in Care Pension Plan’s weighted-average asset allocations by asset category as of December 31, 2016 and 2015 were as follows:


	December 31, 2016			December 31, 2015
Cash and cash equivalents		1.5	%		1.7	%
U.K. government obligation		14.5	%		3.8	%
Annuity contracts		41.6	%		46.5	%
Equity securities		26.3	%		35.7	%
Debt securities		12.1	%		8.5	%
Other		4.0	%		3.8	%

Other Comprehensive Loss (Tables)

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Components Of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):


	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments		Pension Plan			Total
Balance at January 1, 2014	$	—		$	—	$	—		$	—
Foreign currency translation loss		(66,206	)		—		—			(66,206	)
Pension liability adjustment, net of tax of $0.6 million		—			—		(2,164	)		(2,164	)

Balance at December 31, 2014		(66,206	)		—		(2,164	)		(68,370	)
Foreign currency translation loss		(40,103	)		—		—			(40,103	)
Pension liability adjustment, net of tax of $0.9 million		—			—		3,826			3,826

Balance at December 31, 2015		(106,309	)		—		1,662			(104,647	)
Foreign currency translation loss		(477,772	)		—		—			(477,772	)
Gain on derivative instruments, net of tax of $29.1 million		—			40,598		—			40,598
Pension liability adjustment, net of tax of $1.3 million		—			—		(7,749	)		(7,749	)

Balance at December 31, 2016	$	(584,081	)	$	40,598	$	(6,087	)	$	(549,570	)

Quarterly Information (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information


	Quarter Ended
	March 31,		June 30,		September 30,			December 31,
	(In thousands except per share amounts)
2016:
Revenue	$	616,813	$	756,548	$	734,665		$	702,888
Income from continuing operations before income taxes	$	32,479	$	73,852	$	(115,814	)(1)	$	42,438	(2)
Net income attributable to Acadia Healthcare Company, Inc. stockholders	$	25,688	$	56,445	$	(117,808	)(1)	$	41,818	(2)
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.31	$	0.65	$	(1.36	)(1)	$	0.48	(2)
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.31	$	0.65	$	(1.36	)(1)	$	0.48	(2)
2015:
Revenue	$	365,783	$	453,660	$	479,730		$	495,319
Income from continuing operations before income taxes	$	21,205	$	49,355	$	41,645	(3)	$	52,518
Net income attributable to Acadia Healthcare Company, Inc. stockholders	$	14,594	$	33,844	$	29,550	(3)	$	34,566
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.23	$	0.50	$	0.42	(3)	$	0.49
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.23	$	0.49	$	0.42	(3)	$	0.49

(1)	Includes loss on divestiture of $174.7 million and debt extinguishment costs of $3.4 million, or $142.0 million net of taxes, in connection with the U.K. Divestiture and the TLB repricing.

(2)	Includes loss on divestiture of $4.0 million and debt extinguishment costs of $0.8 million, or $3.1 million net of taxes, in connection with the Company’s divestitures and the Refinancing Amendment.

(3)

Financial Information for the Company and Its Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Condensed Consolidating Balance Sheets

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2016

(In thousands)


	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	15,681	$	41,382	$	—		$	57,063
Accounts receivable, net		—		209,124		54,203		—			263,327
Other current assets		—		61,724		45,813		—			107,537

Total current assets		—		286,529		141,398		—			427,927
Property and equipment, net		—		940,880		1,762,815		—			2,703,695
Goodwill		—		1,935,260		745,928		—			2,681,188
Intangible assets, net		—		56,676		26,634		—			83,310
Deferred tax assets – noncurrent		13,522		—		4,606		(14,348	)		3,780
Derivative instruments		73,509		—		—		—			73,509
Investment in subsidiaries		4,885,865		—		—		(4,885,865	)		—
Other assets		493,294		40,480		7,189		(489,646	)		51,317

Total assets	$	5,466,190	$	3,259,825	$	2,688,570	$	(5,389,859	)	$	6,024,726

Current liabilities:
Current portion of long-term debt	$	34,550	$	—	$	255	$	—		$	34,805
Accounts payable		—		49,205		30,829		—			80,034
Accrued salaries and benefits		—		72,835		32,233		—			105,068
Other accrued liabilities		33,616		24,375		64,967		—			122,958

Total current liabilities		68,166		146,415		128,284		—			342,865
Long-term debt		3,230,300		—		512,350		(489,646	)		3,253,004
Deferred tax liabilities – noncurrent		—		40,574		52,294		(14,348	)		78,520
Other liabilities		—		101,938		62,921		—			164,859

Total liabilities		3,298,466		288,927		755,849		(503,994	)		3,839,248

Redeemable noncontrolling interests		—		—		17,754		—			17,754

Total equity		2,167,724		2,970,898		1,914,967		(4,885,865	)		2,167,724

Total liabilities and equity	$	5,466,190	$	3,259,825	$	2,688,570	$	(5,389,859	)	$	6,024,726

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2015

(In thousands)


	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	1,987	$	9,228	$	—		$	11,215
Accounts receivable, net		—		187,546		29,080		—			216,626
Other current assets		—		57,968		8,927		—			66,895

Total current assets		—		247,501		47,235		—			294,736
Property and equipment, net		—		805,439		903,614		—			1,709,053
Goodwill		—		1,835,339		292,876		—			2,128,215
Intangible assets, net		—		57,024		2,551		—			59,575
Deferred tax assets – noncurrent		3,946		40,587		4,581		—			49,114
Investment in subsidiaries		3,495,067		—		—		(3,495,067	)		—
Other assets		427,270		32,947		2,322		(424,024	)		38,515

Total assets	$	3,926,283	$	3,018,837	$	1,253,179	$	(3,919,091	)	$	4,279,208

Current liabilities:
Current portion of long-term debt	$	45,125	$	—	$	235	$	—		$	45,360
Accounts payable		—		75,015		16,326		—			91,341
Accrued salaries and benefits		—		66,249		14,447		—			80,696
Other accrued liabilities		26,132		10,886		35,788		—			72,806

Total current liabilities		71,257		152,150		66,796		—			290,203
Long-term debt		2,171,998		—		447,410		(424,024	)		2,195,384
Deferred tax liabilities – noncurrent		—		—		23,936		—			23,936
Other liabilities		—		75,159		3,443		—			78,602

Total liabilities		2,243,255		227,309		541,585		(424,024	)		2,588,125

Redeemable noncontrolling interests		—		—		8,055		—			8,055

Total equity		1,683,028		2,791,528		703,539		(3,495,067	)		1,683,028

Total liabilities and equity	$	3,926,283	$	3,018,837	$	1,253,179	$	(3,919,091	)	$	4,279,208

Summary of Condensed Consolidating Statement of Comprehensive Income

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Year Ended December 31, 2016

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	1,662,734		$	1,190,089		$	—		$	2,852,823
Provision for doubtful accounts		—			(38,349	)		(3,560	)		—			(41,909	)

Revenue		—			1,624,385			1,186,529			—			2,810,914
Salaries, wages and benefits		28,345			865,104			648,405			—			1,541,854
Professional fees		—			89,062			96,424			—			185,486
Supplies		—			76,246			41,179			—			117,425
Rents and leases		—			34,540			38,808			—			73,348
Other operating expenses		—			206,308			106,248			—			312,556
Depreciation and amortization		—			58,018			77,085			—			135,103
Interest expense, net		50,921			75,848			54,556			—			181,325
Debt extinguishment costs		4,253			—			—			—			4,253
Loss on divestiture		—			778			178,031			—			178,809
Gain on foreign currency derivatives		(523	)		—			—			—			(523	)
Transaction-related expenses		—			32,173			16,150			—			48,323

Total expenses		82,996			1,438,077			1,256,886			—			2,777,959
(Loss) income from continuing operations before income taxes		(82,996	)		186,308			(70,357	)		—			32,955
Equity in earnings of subsidiaries		65,560			—			—			(65,560	)		—
(Benefit from) provision for income taxes		(21,612	)		68,335			(17,944	)		—			28,779

Income (loss) from continuing operations		4,176			117,973			(52,413	)		(65,560	)		4,176
Income from discontinued operations, net of income taxes		—			—			—			—			—

Net income (loss)		4,176			117,973			(52,413	)		(65,560	)		4,176
Net loss attributable to noncontrolling interests		—			—			1,967			—			1,967

Net income attributable to Acadia Healthcare Company, Inc.	$	4,176		$	117,973		$	(50,446	)	$	(65,560	)	$	6,143

Other comprehensive income:
Foreign currency translation gain		—			—			(477,772	)		—			(477,772	)
Gain on derivative instruments		40,598			—			—			—			40,598
Pension liability adjustment, net		—			—			(7,749	)		—			(7,749	)

Other comprehensive income		40,598			—			(485,521	)		—			(444,923	)

Comprehensive income (loss)	$	44,774		$	117,973		$	(535,967	)	$	(65,560	)	$	(438,780	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Year Ended December 31, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	1,415,016		$	414,603		$	—		$	1,829,619
Provision for doubtful accounts		—			(32,614	)		(2,513	)		—			(35,127	)

Revenue		—			1,382,402			412,090			—			1,794,492
Salaries, wages and benefits		20,472			726,215			227,045			—			973,732
Professional fees		—			83,422			33,041			—			116,463
Supplies		—			65,077			15,586			—			80,663
Rents and leases		—			29,094			3,434			—			32,528
Other operating expenses		—			170,018			36,728			—			206,746
Depreciation and amortization		—			41,768			21,782			—			63,550
Interest expense, net		68,533			17,476			20,733			—			106,742
Debt extinguishment costs		10,818			—			—			—			10,818
Loss on foreign currency derivatives		1,926			—			—			—			1,926
Transaction-related expenses		—			24,914			11,657			—			36,571

Total expenses		101,749			1,157,984			370,006			—			1,629,739
(Loss) income from continuing operations before income taxes		(101,749	)		224,418			42,084			—			164,753
Equity in earnings of subsidiaries		176,178			—			—			(176,178	)		—
(Benefit from) provision for income taxes		(37,047	)		85,765			4,670			—			53,388

Income (loss) from continuing operations		111,476			138,653			37,414			(176,178	)		111,365
Income from discontinued operations, net of income taxes		—			111			—			—			111

Net income (loss)		111,476			138,764			37,414			(176,178	)		111,476
Net loss attributable to noncontrolling interests		—			—			1,078			—			1,078

Net income attributable to Acadia Healthcare Company, Inc.	$	111,476		$	138,764		$	38,492		$	(176,178	)	$	112,554

Other comprehensive income:
Foreign currency translation gain		—			—			(40,103	)		—			(40,103	)
Pension liability adjustment, net		—			—			3,826			—			3,826

Other comprehensive income		—			—			(36,277	)		—			(36,277	)

Comprehensive income (loss)	$	111,476		$	138,764		$	2,215		$	(176,178	)	$	76,277

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Year Ended December 31, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	826,465		$	204,319		$	—		$	1,030,784
Provision for doubtful accounts		—			(23,866	)		(2,317	)		—			(26,183	)

Revenue		—			802,599			202,002			—			1,004,601
Salaries, wages and benefits		10,058			459,297			106,057			—			575,412
Professional fees		—			38,632			13,850			—			52,482
Supplies		—			40,511			7,911			—			48,422
Rents and leases		—			10,136			2,065			—			12,201
Other operating expenses		—			83,835			26,819			—			110,654
Depreciation and amortization		—			22,990			9,677			—			32,667
Interest expense, net		27,199			6,207			14,815			—			48,221
Gain on foreign currency derivatives		(15,262	)		—			—			—			(15,262	)
Transaction-related expenses		—			12,367			1,283			—			13,650

Total expenses		21,995			673,975			182,477			—			878,447
(Loss) income from continuing operations before income taxes		(21,995	)		128,624			19,525			—			126,154
Equity in earnings of subsidiaries		97,414			—			—			(97,414	)		—
(Benefit from) provision for income taxes		(7,621	)		44,608			5,935			—			42,922

Income (loss) from continuing operations		83,040			84,016			13,590			(97,414	)		83,232
Loss from discontinued operations, net of income taxes		—			(192	)		—			—			(192	)

Net income (loss)	$	83,040		$	83,824		$	13,590		$	(97,414	)	$	83,040

Other comprehensive loss:
Foreign currency translation loss		—			—			(66,206	)		—			(66,206	)
Pension liability adjustment, net		—			—			(2,164	)		—			(2,164	)

Other comprehensive loss		—			—			(68,370	)		—			(68,370	)

Comprehensive income (loss)	$	83,040		$	83,824		$	(54,780	)	$	(97,414	)	$	14,670

Summary of Condensed Consolidating Statement of Cash Flows

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2016

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	4,176		$	117,973		$	(52,413	)	$	(65,560	)	$	4,176
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(65,560	)		—			—			65,560			—
Depreciation and amortization		—			58,018			77,085			—			135,103
Amortization of debt issuance costs		10,751			—			(427	)		—			10,324
Equity-based compensation expense		28,345			—			—			—			28,345
Deferred income tax (benefit) expense		(2,172	)		50,611			(19,792	)		—			28,647
Loss from discontinued operations, net of taxes		—			—			—			—			—
Debt extinguishment costs		4,253			—			—			—			4,253
Loss on divestiture		—			778			178,031			—			178,809
(Gain) loss on foreign currency derivatives		(523	)		—			—			—			(523	)
Other		—			4,022			693			—			4,715
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(24,017	)		8,299			—			(15,718	)
Other current assets		—			(3,138	)		(17,510	)		—			(20,648	)
Other assets		(3,109	)		(4,048	)		(306	)		3,109			(4,354	)
Accounts payable and other accrued liabilities		—			(45,552	)		68,245			—			22,693
Accrued salaries and benefits		—			3,844			(12,416	)		—			(8,572	)
Other liabilities		—			4,050			434			—			4,484

Net cash (used in) provided by continuing operating activities		(23,839	)		162,541			229,923			3,109			371,734
Net cash used in discontinued operating activities		—			(10,256	)		—			—			(10,256	)

Net cash (used in) provided by operating activities		(23,839	)		152,285			229,923			3,109			361,478
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(103,359	)		(580,096	)		—			(683,455	)
Cash paid for capital expenditures		—			(177,593	)		(129,879	)		—			(307,472	)
Cash paid for real estate acquisitions		—			(28,956	)		(11,801	)		—			(40,757	)
Settlement of foreign currency derivatives		—			523			—			—			523
Cash received for divestiture		370,000			7,859			(4,593	)		—			373,266
Other		—			(1,573	)		(897	)		—			(2,470	)

Net cash used in investing activities		370,000			(303,099	)		(727,266	)		—			(660,365	)
Financing activities:
Borrowings on long-term debt		1,480,000			—			—			—			1,480,000
Borrowings on revolving credit facility		179,000			—			—			—			179,000
Principal payments on revolving credit facility		(337,000	)		—			—			—			(337,000	)
Principal payments on long-term debt		(49,706	)		(293,000	)		(3,344	)		296,109			(49,941	)
Repayment of assumed debt		(1,348,389	)		—			—			—			(1,348,389	)
Repayment of long-term debt		(200,594	)		—			—			—			(200,594	)
Payment of debt issuance costs		(36,649	)		—			—			—			(36,649	)
Issuance of common stock		685,097			—			—			—			685,097
Common stock withheld for minimum statutory taxes, net		(8,846	)		—			—			—			(8,846	)
Excess tax benefit from equity awards		—			—			—			—			—
Other		(1,149	)		(2,688	)		—			—			(3,837	)
Cash (used in) provided by intercompany activity		(707,925	)		460,196			546,947			(299,218	)		—

Net cash provided by (used in) financing activities		(346,161	)		164,508			543,603			(3,109	)		358,841

Effect of exchange rate changes on cash		—			—			(14,106	)		—			(14,106	)

Net increase in cash and cash equivalents		—			13,694			32,154			—			45,848
Cash and cash equivalents at beginning of the period		—			1,987			9,228			—			11,215

Cash and cash equivalents at end of the period	$	—		$	15,681		$	41,382		$	—		$	57,063

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2015

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	111,476		$	138,764		$	37,414		$	(176,178	)	$	111,476
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(176,178	)		—			—			176,178			—
Depreciation and amortization		—			41,768			21,782			—			63,550
Amortization of debt issuance costs		7,147			—			(438	)		—			6,709
Equity-based compensation expense		20,472			—			—			—			20,472
Deferred income tax (benefit) expense		617			42,246			750			—			43,613
Loss from discontinued operations, net of taxes		—			(111	)		—			—			(111	)
Debt extinguishment costs		10,818			—			—			—			10,818
Loss (gain) on foreign currency derivatives		1,926			—			—			—			1,926
Other		—			1,582			33			—			1,615
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(18,632	)		(6,322	)		—			(24,954	)
Other current assets		—			(1,152	)		(1,565	)		—			(2,717	)
Other assets		(1,100	)		(8,567	)		546			1,100			(8,021	)
Accounts payable and other accrued liabilities		—			(7,583	)		14,451			—			6,868
Accrued salaries and benefits		—			312			1,346			—			1,658
Other liabilities		—			9,350			(114	)		—			9,236

Net cash (used in) provided by continuing operating activities		(24,822	)		197,977			67,883			1,100			242,138
Net cash provided by discontinued operating activities		—			(1,735	)		—			—			(1,735	)

Net cash (used in) provided by operating activities		(24,822	)		196,242			67,883			1,100			240,403
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(254,848	)		(319,929	)		—			(574,777	)
Cash paid for capital expenditures		—			(172,329	)		(103,718	)		—			(276,047	)
Cash paid for real estate acquisitions		—			(25,293	)		(1,329	)		—			(26,622	)
Settlement of foreign currency derivatives		—			(1,926	)		—			—			(1,926	)
Other		—			(5,099	)		—			—			(5,099	)

Net cash used in investing activities		—			(459,495	)		(424,976	)		—			(884,471	)
Financing activities:
Borrowings on long-term debt		1,150,000			—			—			—			1,150,000
Borrowings on revolving credit facility		468,000			—			—			—			468,000
Principal payments on revolving credit facility		(310,000	)		—			—			—			(310,000	)
Principal payments on long-term debt		(31,965	)		—			(1,315	)		1,315			(31,965	)
Repayment of assumed CRC debt		(904,467	)		—			—			—			(904,467	)
Repayments of senior notes		(97,500	)		—			—			—			(97,500	)
Payment of debt issuance costs		(26,421	)		—			—			—			(26,421	)
Payment of premium on senior notes		(7,480	)		—			—			—			(7,480	)
Issuance of Common Stock		331,308			—			—			—			331,308
Common stock withheld for minimum statutory taxes, net		(7,762	)		—			—			—			(7,762	)
Excess tax benefit from equity awards		309			—			—			—			309
Other		—			(420	)		—			—			(420	)
Cash provided by (used in) intercompany activity		(539,200	)		191,334			350,281			(2,415	)		—

Net cash provided by (used in) financing activities		24,822			190,914			348,966			(1,100	)		563,602

Effect of exchange rate changes on cash		—			(2,359	)		—			—			(2,359	)

Net (decrease) increase in cash and cash equivalents		—			(74,698	)		(8,127	)		—			(82,825	)
Cash and cash equivalents at beginning of the period		—			76,685			17,355			—			94,040

Cash and cash equivalents at end of the period	$	—		$	1,987		$	9,228		$	—		$	11,215

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2014

(In thousands)


	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	83,040		$	83,824		$	13,590		$	(97,414	)	$	83,040
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(97,414	)		—			—			97,414			—
Depreciation and amortization		—			22,990			9,677			—			32,667
Amortization of debt issuance costs		2,748			—			450			—			3,198
Equity-based compensation expense		10,058			—			—			—			10,058
Deferred income tax (benefit) expense		(1,969	)		5,231			3,953			—			7,215
Loss from discontinued operations, net of taxes		—			192			—			—			192
Gain on foreign currency derivatives		(15,262	)		—			—			—			(15,262	)
Other		—			449			39			—			488
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(13,636	)		(1,474	)		—			(15,110	)
Other current assets		—			(2,205	)		194			—			(2,011	)
Other assets		(1,151	)		(6,910	)		397			1,151			(6,513	)
Accounts payable and other accrued liabilities		—			(5,559	)		8,352			—			2,793
Accrued salaries and benefits		—			11,035			945			—			11,980
Other liabilities		—			1,769			980			—			2,749

Net cash (used in) provided by continuing operating activities		(19,950	)		97,180			37,103			1,151			115,484
Net cash used in discontinued operating activities		—			(198	)		—			—			(198	)

Net cash (used in) provided by operating activities		(19,950	)		96,982			37,103			1,151			115,286
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(723,064	)		(15,638	)		—			(738,702	)
Cash paid for capital expenditures		—			(83,864	)		(29,380	)		—			(113,244	)
Cash paid for real estate acquisitions		—			(23,177	)		—			—			(23,177	)
Settlement of foreign currency derivatives		15,262			—			—			—			15,262
Other		—			(913	)		—			—			(913	)

Net cash used in investing activities		15,262			(831,018	)		(45,018	)		—			(860,774	)
Financing activities:
Borrowings on long-term debt		542,500			—			—			—			542,500
Borrowings on revolving credit facility		230,500			—			—			—			230,500
Principal payments on revolving credit facility		(284,000	)		—			—			—			(284,000	)
Principal payments on long-term debt		(7,500	)		—			(1,346	)		1,151			(7,695	)
Payment of debt issuance costs		(12,993	)		—			—			—			(12,993	)
Issuance of common stock, net		374,431			—			—			—			374,431
Common stock withheld for minimum statutory taxes, net		(4,099	)		—			—			—			(4,099	)
Excess tax benefit from equity awards		4,617			—			—			—			4,617
Cash paid for contingent consideration		—			(5,000	)		—			—			(5,000	)
Other		—			(289	)		—			—			(289	)
Cash (used in) provided by intercompany activity		(838,768	)		816,010			23,135			(377	)		—

Net cash provided by financing activities		4,688			810,721			21,789			774			837,972

Effect of exchange rate changes on cash		—			—			(3,013	)		—			(3,013	)

Net increase in cash and cash equivalents		—			76,685			10,861			1,925			89,471
Cash and cash equivalents at beginning of the period		—			—			6,494			(1,925	)		4,569

Cash and cash equivalents at end of the period	$	—		$	76,685		$	17,355		$	—		$	94,040

Description of Business and Basis of Presentation - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($) State Beds Facilities	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Accounting Policies [Abstract]
Number of facilities \| Facilities	573
Number of beds \| Beds	17,100
Number of operating states \| State	39
General and administrative expenses \| $	$ 86.8	$ 68.3	$ 36.9

Summary of Significant Accounting Policies - Summary of Percentage of Revenue before Provision for Doubtful Accounts Generated by Each Payor Type (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	100.00%	100.00%	100.00%
Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	18.70%	23.10%	23.00%
Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	9.40%	11.70%	19.40%
Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	25.40%	33.30%	38.30%
U.K Public Funded Sources [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	35.80%	19.50%	14.50%
Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	9.40%	9.60%	2.50%
Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	1.30%	2.80%	2.30%

Summary of Significant Accounting Policies - Additional Information (Detail)	4 Months Ended	12 Months Ended
	Dec. 31, 2016 USD ($)	Dec. 31, 2016 USD ($) Segment	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Summary Of Significant Policies [Line Items]
Percentage of revenue		100.00%	100.00%	100.00%
Cost report receivables	$ 7,400,000	$ 7,400,000	$ 4,200,000
Net adjustments to estimated cost report settlements resulted in increases to revenue		700,000	1,900,000	$ 300,000
Costs of providing charity care services		7,100,000	4,600,000	2,500,000
Professional liability risks, amount	50,000,000
Professional and general liability reserve	52,300,000	52,300,000	41,900,000
Professional and general liability reserve current	11,700,000	11,700,000	10,500,000
Professional and general liability reserve noncurrent	40,600,000	40,600,000	31,400,000
Insurance receivable	25,900,000	25,900,000	21,300,000
Insurance receivable - current portion	6,472,000	6,472,000	5,290,000
Insurance receivable noncurrent	19,400,000	19,400,000	16,000,000
Workers compensation insurance claims deductible per accident		500,000
Reserve for workers compensation liability		16,600,000	14,700,000
Accrued salaries and benefits	10,000,000	10,000,000	7,500,000
Other long-term liabilities	6,600,000	6,600,000	7,200,000
Depreciation expense		$ 134,800,000	63,000,000	32,100,000
Number of operating segment \| Segment		2
Number of reporting unit \| Segment		2
Intangible assets impairment charges		$ 0	$ 0	$ 0
Minimum [Member]
Summary Of Significant Policies [Line Items]
Maximum professional liability insurance per incident	2,000,000
Minimum [Member] \| Buildings and Improvements [Member]
Summary Of Significant Policies [Line Items]
Property plant and equipment estimated useful life		10 years
Minimum [Member] \| Equipment [Member]
Summary Of Significant Policies [Line Items]
Property plant and equipment estimated useful life		3 years
Maximum [Member]
Summary Of Significant Policies [Line Items]
Maximum professional liability aggregate policy limit	$ 52,000,000
Maximum [Member] \| Buildings and Improvements [Member]
Summary Of Significant Policies [Line Items]
Property plant and equipment estimated useful life		50 years
Maximum [Member] \| Equipment [Member]
Summary Of Significant Policies [Line Items]
Property plant and equipment estimated useful life		7 years
United Kingdom [Member]
Summary Of Significant Policies [Line Items]
Percentage of revenue generated by facility		38.00%	20.00%	15.00%
Arkansas [Member]
Summary Of Significant Policies [Line Items]
Percentage of revenue generated by facility				12.00%
Medicare and Medicaid [Member]
Summary Of Significant Policies [Line Items]
Percentage of revenue		35.00%	45.00%	58.00%

Summary of Significant Accounting Policies - Summary of Activity in Company's Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Receivables [Abstract]
Balance at Beginning of Period	$ 29,332	$ 22,449	$ 18,345
Additions Charged to Costs and Expenses	41,909	35,127	26,183
Accounts Written Off, Net of Recoveries	(32,325)	(28,244)	(22,079)
Balance at End of Period	$ 38,916	$ 29,332	$ 22,449

Summary of Significant Accounting Policies - Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other receivables	$ 44,975	$ 17,518
Prepaid expenses	27,455	21,817
Income taxes receivable	11,714	6,540
Workers' compensation deposits - current portion	10,000	7,500
Insurance receivable - current portion	6,472	5,290
Inventory	4,633	4,681
Other	2,288	3,549
Other current assets	$ 107,537	$ 66,895

Summary of Significant Accounting Policies - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued expenses	$ 37,323	$ 17,921
Accrued interest	33,616	26,132
Unearned income	28,805	446
Insurance liability - current portion	11,672	10,490
Accrued property taxes	2,732	2,951
Other	8,283	7,499
Income taxes payable	527	7,367
Other accrued liabilities	$ 122,958	$ 72,806

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

Earnings Per Share - Computation of Basic and Diluted Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations									$ 6,143	$ 112,443	$ 83,232
Income (loss) from discontinued operation										111	(192)
Net income attributable to Acadia Healthcare Company, Inc.	$ 41,818	$ (117,808)	$ 56,445	$ 25,688	$ 34,566	$ 29,550	$ 33,844	$ 14,594	$ 6,143	$ 112,554	$ 83,040
Denominator:
Weighted average shares outstanding for basic earnings per share									85,701	68,085	55,063
Effects of dilutive instruments									271	306	264
Shares used in computing diluted earnings per common share									85,972	68,391	55,327
Basic earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations									$ 0.07	$ 1.65	$ 1.51
Income (loss) from discontinued operations									0	0	0
Net income attributable to Acadia Healthcare Company, Inc.:	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 0.49	$ 0.42	$ 0.50	$ 0.23	0.07	1.65	1.51
Diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations									0.07	1.64	1.50
Income (loss) from discontinued operations									0	0	0
Net income attributable to Acadia Healthcare Company, Inc.:	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 0.49	$ 0.42	$ 0.49	$ 0.23	$ 0.07	$ 1.64	$ 1.50

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	1.1	0.8	0.7

Acquisitions - 2016 US Acquisitions - Additional Information (Detail)	Jun. 01, 2016 USD ($) Beds	May 01, 2016 USD ($) Beds	Apr. 01, 2016 USD ($) Beds
Pocono Mountain Recovery Center [Member]
Business Acquisition [Line Items]
Number of beds \| Beds	108
Business acquisition cash consideration	$ 25,400,000
Cash payments for earn-out agreement	$ 5,000,000
Serenity Knolls Inc [Member]
Business Acquisition [Line Items]
Number of beds \| Beds			30
Business acquisition cash paid			$ 9,700,000
Tennessee [Member] \| TrustPoint Hospital [Member]
Business Acquisition [Line Items]
Number of beds \| Beds		100
Business acquisition cash paid		$ 62,700,000

Acquisitions - Priory Acquisition - Additional Information (Detail) $ in Thousands, £ in Millions				3 Months Ended								12 Months Ended
	Nov. 30, 2016 GBP (£)	Oct. 18, 2016 Bed Facility	Feb. 16, 2016 USD ($) Bed Facility shares	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Business Acquisition [Line Items]
Number of beds to be sold \| Bed		1,000
Cash received from sale of business	£ 320											$ 373,266
Loss on divestiture												(178,809)
Revenue												2,810,914	$ 1,794,492	$ 1,004,601
Income from continuing operations before income taxes				$ 42,438	$ (115,814)	$ 73,852	$ 32,479	$ 52,518	$ 41,645	$ 49,355	$ 21,205	32,955	164,753	$ 126,154
U.K. Behavioral Health Facilities [Member]
Business Acquisition [Line Items]
Number of facilities to be sold \| Facility		21
De novo Behavioral Health Facility [Member]
Business Acquisition [Line Items]
Number of facilities to be sold \| Facility		1
U.K. Disposal Group [Member]
Business Acquisition [Line Items]
Loss on divestiture					$ 174,700							175,000
Revenue												154,700	58,500
Income from continuing operations before income taxes												81,200	$ 17,000
U.K. Disposal Group [Member] \| Allocation of Goodwill [Member]
Business Acquisition [Line Items]
Loss on divestiture												106,900
U.K. Disposal Group [Member] \| Estimated Transaction Related Expense [Member]
Business Acquisition [Line Items]
Loss on divestiture												26,100
U.K. Disposal Group [Member] \| Loss on Sale of Properties [Member]
Business Acquisition [Line Items]
Loss on divestiture												$ 42,000
Priory [Member]
Business Acquisition [Line Items]
Total consideration related to acquisition			$ 2,200,000
Business acquisition cash paid			$ 1,900,000
Shares issued for acquisition \| shares			4,033,561
Number of facilities acquired \| Facility			324
Number of beds \| Bed			7,100

Acquisitions - 2015 US Acquisitions - Additional Information (Detail) $ in Millions	Dec. 01, 2015 USD ($) Beds Facility	Nov. 01, 2015 USD ($) State Beds Center	Jul. 01, 2015 USD ($) Beds	Mar. 01, 2015 USD ($) Center	Feb. 11, 2015 USD ($) State Beds Center Facilities shares	Dec. 31, 2016 State	Aug. 31, 2015 USD ($)
Business Acquisition [Line Items]
Number of operating states \| State						39
MMO Behavioral Health Systems [Member]
Business Acquisition [Line Items]
Number of beds \| Beds	80
Business acquisition cash paid	$ 20.2
Number of facilities acquired \| Facility	2
Discovery House-Group Inc [Member]
Business Acquisition [Line Items]
Business acquisition cash paid		$ 118.3
Number of facilities acquired \| Center		19
Number of operating states \| State		4
Duffys Napa Valley Rehab [Member]
Business Acquisition [Line Items]
Number of beds \| Beds		61
Business acquisition cash paid		$ 29.6
Quality Addiction Management [Member]
Business Acquisition [Line Items]
Business acquisition cash paid				$ 54.8
Number of facilities acquired \| Center				7
CRC Health Group, Inc [Member]
Business Acquisition [Line Items]
Number of facilities acquired \| Center					81
Number of operating states \| State					30
Total consideration related to acquisition					$ 1,300.0
Shares issued for acquisition \| shares					5,975,326
Outstanding indebtedness of CRC repaid					$ 904.5
Number of inpatient facilities \| Facilities					35
CRC Health Group, Inc [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Number of beds \| Beds					2,400
Massachusetts [Member] \| Southcoast Behavioral [Member]
Business Acquisition [Line Items]
Approximate value of noncontrolling interest							$ 9.2
Equity ownership interests percentage in the facility							75.00%
Percentage of noncontrolling interests in the facility							25.00%
Pennsylvania [Member] \| Belmont Behavioral Health [Member]
Business Acquisition [Line Items]
Number of beds \| Beds			147
Business acquisition cash paid			$ 39.0
Total consideration related to acquisition			35.0
Working capital settlement			$ 4.0

Acquisitions - 2015 UK Acquisitions - Additional Information (Detail) - United Kingdom [Member] $ in Millions	Nov. 01, 2015 USD ($) Beds	Oct. 01, 2015 USD ($) Beds	Sep. 01, 2015 USD ($) Beds Facility	Jul. 01, 2015 USD ($) Beds	Jun. 01, 2015 USD ($) Beds Facility	Apr. 01, 2015 USD ($) Beds Facility
Care UK Limited [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $					$ 88.2
Number of beds \| Beds					299
Number of facilities acquired \| Facility					15
Choice Lifestyles [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $					$ 25.9	$ 37.5
Number of beds \| Beds					42	48
Number of facilities acquired \| Facility					1	2
Pastoral Care Group [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $						$ 34.2
Number of beds \| Beds						65
Number of facilities acquired \| Facility						2
Mildmay Oaks [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $						$ 14.9
Number of beds \| Beds						67
Cleveland House [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $	$ 10.3
Number of beds \| Beds	32
Meadow View [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $		$ 6.8
Number of beds \| Beds		28
Health and Social Care Partnerships [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $			$ 26.2
Number of beds \| Beds			50
Number of facilities acquired \| Facility			2
The Danshell Group [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $			$ 59.8
Number of beds \| Beds			73
Number of facilities acquired \| Facility			3
Manor Hall [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $			$ 14.0
Number of beds \| Beds			26
The Manor Clinic [Member]
Business Acquisition [Line Items]
Business acquisition cash paid \| $				$ 5.9
Number of beds \| Beds				15

Acquisitions - Summary of Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 2,681,188	$ 2,128,215
Domestic Acquisitions in 2015 and 2014 [Member]
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 319,400	$ 319,400

Acquisitions - Priory Acquisition (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 2,681,188	$ 2,128,215
2016 Acquisitions [Member]
Business Acquisition [Line Items]
Cash	12,741
Accounts receivable	62,121
Prepaid expenses and other current assets	8,064
Property and equipment	1,633,556
Goodwill	781,794
Intangible assets	23,538
Other assets	7,807
Total assets acquired	2,529,621
Accounts payable	25,008
Accrued salaries and benefits	40,385
Other accrued expenses	48,695
Deferred tax liabilities - noncurrent	60,241
Debt	1,348,389
Other liabilities	93,825
Total liabilities assumed	1,616,543
Net assets acquired	913,078
Priory [Member] \| 2016 Acquisitions [Member]
Business Acquisition [Line Items]
Cash	10,253
Accounts receivable	57,832
Prepaid expenses and other current assets	7,921
Property and equipment	1,598,156
Goodwill	686,149
Intangible assets	23,200
Other assets	7,760
Total assets acquired	2,391,271
Accounts payable	24,203
Accrued salaries and benefits	39,588
Other accrued expenses	48,305
Deferred tax liabilities - noncurrent	59,972
Debt	1,348,389
Other liabilities	63,583
Total liabilities assumed	1,584,040
Net assets acquired	807,231
Other [Member] \| 2016 Acquisitions [Member]
Business Acquisition [Line Items]
Cash	2,488
Accounts receivable	4,289
Prepaid expenses and other current assets	143
Property and equipment	35,400
Goodwill	95,645
Intangible assets	338
Other assets	47
Total assets acquired	138,350
Accounts payable	805
Accrued salaries and benefits	797
Other accrued expenses	390
Deferred tax liabilities - noncurrent	269
Other liabilities	30,242
Total liabilities assumed	32,503
Net assets acquired	$ 105,847

Acquisitions - Summary of Acquisitions (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 2,681,188	$ 2,128,215
2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		24,933
Accounts receivable		67,480
Prepaid expenses and other current assets		29,500
Property and equipment		409,306
Goodwill		1,361,337
Intangible assets		37,204
Deferred tax asset-noncurrent		78,664
Other assets		6,529
Total assets acquired		2,014,953
Accounts payable		9,702
Accrued salaries and benefits		18,027
Other accrued expenses		44,655
Deferred tax liabilities - noncurrent		13,541
Debt		904,467
Other liabilities		34,730
Total liabilities assumed		1,025,122
Redeemable noncontrolling interests		9,132
Net assets acquired		980,699
Other [Member] \| 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		5,334
Accounts receivable		20,445
Prepaid expenses and other current assets		2,555
Property and equipment		273,143
Goodwill		322,017
Intangible assets		204
Other assets		51
Total assets acquired		623,749
Accounts payable		4,961
Accrued salaries and benefits		3,200
Other accrued expenses		5,782
Deferred tax liabilities - noncurrent		13,541
Other liabilities		10
Total liabilities assumed		27,494
Redeemable noncontrolling interests		9,132
Net assets acquired		587,123
CRC Health Group, Inc [Member] \| 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		19,599
Accounts receivable		47,035
Prepaid expenses and other current assets		26,945
Property and equipment		136,163
Goodwill		1,039,320
Intangible assets		37,000
Deferred tax asset-noncurrent		78,664
Other assets		6,478
Total assets acquired		1,391,204
Accounts payable		4,741
Accrued salaries and benefits		14,827
Other accrued expenses		38,873
Debt		904,467
Other liabilities		34,720
Total liabilities assumed		997,628
Net assets acquired		$ 393,576

Acquisitions - Other (Detail) - USD ($) $ in Thousands	12 Months Ended
Acquisitions - Other (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Combinations [Abstract]
Legal, accounting and other fees	$ 21,058	$ 17,768	$ 12,836
Advisory and financing commitment fees	14,850	10,337
Severance and contract termination costs	12,415	8,466	814
Transaction-related expenses	$ 48,323	$ 36,571	$ 13,650

Acquisitions - Pro Forma Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Revenue									$ 2,810,914	$ 1,794,492	$ 1,004,601
Income from continuing operations before income taxes	$ 42,438	$ (115,814)	$ 73,852	$ 32,479	$ 52,518	$ 41,645	$ 49,355	$ 21,205	32,955	164,753	$ 126,154
Acquisitions 2016 [Member]
Business Acquisition [Line Items]
Revenue									1,500
Income from continuing operations before income taxes									$ 74,800
Acquisitions 2015 [Member]
Business Acquisition [Line Items]
Revenue										552,100
Income from continuing operations before income taxes										$ 204,100

Acquisitions - Pro Forma Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Combinations [Abstract]
Revenue	$ 2,765,221	$ 2,715,749
Income from continuing operations, before income taxes	$ 173,707	$ 113,297

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,247	$ 3,347
Intangible assets not subject to amortization, Gross Carrying Amount	83,310	59,225
Total	86,557	62,572
Intangible assets subject to amortization, Accumulated Amortization	(3,247)	(2,997)
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(3,247)	(2,997)
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(2,100)	(1,750)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,147	1,247
Intangible assets subject to amortization, Accumulated Amortization	(1,147)	(1,247)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	12,228	11,479
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	57,538	37,800
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	13,544	9,946
Intangible assets not subject to amortization, Accumulated Amortization	$ 0	$ 0

Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0.4	$ 0.5	$ 0.6

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Sep. 21, 2015
Debt Instrument [Line Items]
Less: unamortized debt issuance costs, discount and premium	$ (59,816)	$ (35,416)
Long-term debt	3,287,809	2,240,744
Long-term debt	3,287,809	2,240,744
Less: current portion	(34,805)	(45,360)
Long-term debt	3,253,004	2,195,384
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes	150,000	150,000
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes	300,000	300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	650,000	650,000	$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes	390,000
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Senior Secured	400,000	500,750
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	1,435,450	495,000
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Senior Secured		158,000
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 22,175	$ 22,410

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
Senior notes maturity year	2021	2021
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
Senior notes maturity year	2022	2022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
Senior notes maturity year	2023	2023
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%		6.50%
Senior notes maturity year	2024
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%	9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%	9.50%

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($)										3 Months Ended				12 Months Ended
	Nov. 30, 2016	Sep. 21, 2016	Sep. 20, 2016	May 26, 2016	May 25, 2016	Feb. 16, 2016	Dec. 15, 2015	Dec. 31, 2012	Apr. 01, 2011	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Nov. 22, 2016	Feb. 11, 2015	Feb. 06, 2015	Dec. 15, 2014
Debt Instrument [Line Items]
Debt extinguishment costs														$ (4,253,000)	$ (10,818,000)
Line of Credit Facility, Expiration Date	Feb. 13, 2019
Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA																			$ 40,000,000
Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit	$ 300,000,000
Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit	600,600,000
Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings														2.75%
Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings														1.75%
Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement								Dec. 31, 2012	Apr. 01, 2011
Additional term loans						$ 135,000,000
Debt extinguishment costs	$ 800,000
Line of Credit Facility, Expiration Date	Nov. 30, 2021
Debt Instrument, Interest Rate, Decrease	0.50%
Amount available under revolving line of credit										$ 491,700,000				$ 491,700,000
Debt instrument maturity date							Nov. 30, 2021							Feb. 11, 2022
Term loan repayments													$ 1,300,000
Amended and Restated Senior Credit Facility [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Fair market value of real property																$ 5,000,000
Amended and Restated Senior Credit Facility [Member] \| Tranche B-2 Repricing Amendment [Member]
Debt Instrument [Line Items]
Debt extinguishment costs														$ 3,400,000
Amended and Restated Senior Credit Facility [Member] \| Seventh Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement														Feb. 06, 2015
Amended and Restated Senior Credit Facility [Member] \| Ninth Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement														Jan. 25, 2016
Restrictive covenants on investments, Description														The Ninth Amendment modifies certain definitions and provides increased flexibility to the Company in terms of its financial covenants. The Company’s baskets for permitted investments were also increased to provide increased flexibility for it to invest in non-wholly owned subsidiaries, joint ventures and foreign subsidiaries. The Company may now invest in non-wholly owned subsidiaries and joint ventures up to 10.0% of the Company and its subsidiaries’ total assets in any four consecutive fiscal quarter period, and up to 12.5% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The Company may also invest in foreign subsidiaries that are not loan parties up to 10% of the Company and its subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 15% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 25% of the Company and its subsidiaries’ total assets in any fiscal year.
Amended and Restated Senior Credit Facility [Member] \| Second Incremental Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement														Feb. 16, 2016
New incremental Term Loan B facility						955,000,000
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit	$ 500,000,000					$ 300,000,000
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member]
Debt Instrument [Line Items]
Term loan repayments													$ 2,400,000
Amended and Restated Senior Credit Facility [Member] \| Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit	$ 400,000,000
Amended and Restated Senior Credit Facility [Member] \| Standby Letters of Credit [Member]
Debt Instrument [Line Items]
New incremental Term Loan B facility										8,300,000				$ 8,300,000
Amended and Restated Senior Credit Facility [Member] \| Letter of Credit [Member] \| Seventh Amendment [Member]
Debt Instrument [Line Items]
Line of credit																		$ 20,000,000
Amended and Restated Senior Credit Facility [Member] \| Swing Line Sublimit [Member] \| Seventh Amendment [Member]
Debt Instrument [Line Items]
Line of credit																		$ 20,000,000
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Basis spread on variable rate														1.00%
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member] \| Tranche B-1 Repricing Amendment [Member]
Debt Instrument [Line Items]
Interest on borrowings				3.00%	3.50%
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member] \| Tranche B-2 Repricing Amendment [Member]
Debt Instrument [Line Items]
Interest on borrowings		3.00%	3.75%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate														0.50%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member] \| Tranche B-1 Repricing Amendment [Member]
Debt Instrument [Line Items]
Interest on borrowings				2.00%	2.50%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member] \| Tranche B-2 Repricing Amendment [Member]
Debt Instrument [Line Items]
Interest on borrowings		2.00%	2.75%
Amended and Restated Senior Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings														2.75%
Amended and Restated Senior Credit Facility [Member] \| Senior Debt Obligations [Member] \| First Incremental Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement														Feb. 11, 2015
Line of credit																	$ 500,000,000
Amended and Restated Senior Credit Facility [Member] \| March 31, 2017 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan principal repayments							$ 5,000,000
Term loan repayments												$ 1,300,000
Amended and Restated Senior Credit Facility [Member] \| March 31, 2017 to December 31, 2019 [Member] \| TLB Facility Due on February 16, 2023 [Member]
Debt Instrument [Line Items]
Term loan repayments												$ 2,400,000
Amended and Restated Senior Credit Facility [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments											$ 1,300,000
Amended and Restated Senior Credit Facility [Member] \| September 30, 2015 to December 31, 2015 [Member] \| TLB Facility Due on February 16, 2023 [Member]
Debt Instrument [Line Items]
Term loan repayments											$ 2,400,000
Amended and Restated Senior Credit Facility [Member] \| March 31, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan principal repayments							7,500,000
Term loan repayments										1,300,000
Amended and Restated Senior Credit Facility [Member] \| March 31, 2020 to December 31, 2020 [Member] \| TLB Facility Due on February 16, 2023 [Member]
Debt Instrument [Line Items]
Term loan repayments										$ 2,400,000
Amended and Restated Senior Credit Facility [Member] \| March 31, 2021 to September 30, 2021 [Member]
Debt Instrument [Line Items]
Term loan principal repayments							$ 10,000,000

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)		12 Months Ended
	Mar. 12, 2013	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		Payable semi-annually in arrears on March 15 and September 15 of each year.

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)		12 Months Ended
	Jul. 01, 2014	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		Payable semi-annually in arrears on January 1 and July 1 of each year.

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes			$ 275,000,000	$ 375,000,000
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior Notes	$ 650,000,000	$ 650,000,000	$ 650,000,000
Debt instrument maturity date	Feb. 15, 2023

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)		12 Months Ended
	Feb. 16, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000
Debt instrument interest rate	6.50%	6.50%
Debt instrument maturity date	Mar. 01, 2024
Interest on the notes		Payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

Long-Term Debt (9.0% and 9.5% Revenue Bonds) - Additional Information (Detail) - USD ($) $ in Thousands	Nov. 11, 2012	Dec. 31, 2016	Dec. 31, 2015
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds		$ 22,175	$ 22,410
9.0% and 9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 23,000
Debt service reserve fund within other assets		$ 2,300	$ 2,300
Debt instrument premium	2,600
9.0% and 9.5% Revenue Bonds [Member] \| Fair Value [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	25,600
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.00%	9.00%
9.0% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 7,500
Debt instrument interest rate	9.00%
Debt instrument maturity date	Dec. 01, 2030
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.50%	9.50%
9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 15,500
Debt instrument interest rate	9.50%
Debt instrument maturity date	Dec. 01, 2040

Long-Term Debt (Debt Issuance Costs) - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt issuance costs	$ 10,324	$ 6,709	$ 3,198
Accumulated amortization	21,600	12,600
Amortization expenses reported as interest expense	10,800	$ 7,100
Estimated amortization of debt issuance costs year one	9,300
Estimated amortization of debt issuance costs year two	9,700
Estimated amortization of debt issuance costs year three	10,000
Estimated amortization of debt issuance costs year four	10,400
Estimated amortization of debt issuance costs year five	$ 10,200

Long-Term Debt (Other) - Summary of Aggregate Maturities of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Debt Disclosure [Abstract]
2017	$ 34,805
2018	34,830
2019	34,855
2020	44,880
2021	474,910
Thereafter	2,723,345
Total	$ 3,347,625

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands					12 Months Ended
	Feb. 16, 2016	Jan. 12, 2016	May 11, 2015	Feb. 11, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 03, 2016
Equity [Line Items]
Preferred stock, number of shares proposed to be issued					10,000,000	10,000,000
Common stock, number of shares proposed to be issued					180,000,000	90,000,000
Common stock voting rights					One vote for each share
Common stock offered		11,500,000	5,175,000		86,688,199	70,745,746
Common stock offer price		$ 61.00	$ 66.50		$ 0.01	$ 0.01
Underwriting discount amount		$ 15,800	$ 12,000
Additional offering-related costs		700	800
Net proceeds from sale of shares		$ 685,000	$ 331,300		$ 216,882	$ 380,210
CRC Health Group, Inc [Member]
Equity [Line Items]
Total consideration related to acquisition				$ 1,300,000
Shares issued for acquisition				5,975,326
Priory [Member]
Equity [Line Items]
Total consideration related to acquisition	$ 2,200,000
Shares issued for acquisition	4,033,561
Business acquisition cash paid	$ 1,900,000
Maximum [Member]
Equity [Line Items]
Preferred stock, number of shares proposed to be issued					10,000,000
Maximum [Member] \| Amendment [Member]
Equity [Line Items]
Common stock, number of shares proposed to be issued							180,000,000

Equity-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	8,200,000
Equity incentive plan available for future grant	4,645,213
Annual increments in employee grants	25.00%
Stock options, contractual term	10 years
Equity-based compensation expense	$ 28,345	$ 20,472	$ 10,058
Unrecognized compensation expense related to unvested options	$ 51,000
Vesting period	1 year 2 months 12 days
Warrants outstanding	0
Deferred income tax benefit	$ 28,647	43,613	7,215
Tax realized from stock options exercised		300	$ 4,600
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 10,700	$ 8,400

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options outstanding, Beginning balance	694,743	737,422
Options granted	503,850	204,700
Options exercised	(57,397)	(214,079)
Options cancelled	(140,250)	(33,300)
Options outstanding, Ending balance	1,000,946	694,743	737,422
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 42.87	$ 32.19
Options exercisable, Ending balance	288,959	106,330
Options granted, Weighted Average Exercise Price	$ 57.98	$ 63.07
Options exercised, Weighted Average Exercise Price	31.92	42.75
Options cancelled, Weighted Average Exercise Price	57.13	46.53
Options outstanding, Weighted Average Exercise Price, Ending balance	$ 49.42	$ 42.87	$ 32.19
Options outstanding, Aggregate Intrinsic Value, Beginning balance	$ 20,717	$ 14,512
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 42.81	$ 36.41
Options granted, Aggregate Intrinsic Value	$ 297	$ 1,724
Options granted, Weighted Average Remaining Contractual Term	9 years 3 months 11 days	9 years 2 months 16 days
Options exercised, Aggregate Intrinsic Value	$ 1,530	$ 9,890
Options outstanding, Weighted Average Remaining Contractual Term	7 years 9 months 18 days	7 years 8 months 12 days	8 years 1 month 2 days
Options cancelled, Aggregate Intrinsic Value	$ 0	$ 0
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	6 years 2 months 19 days	5 years 9 months 29 days
Options outstanding, Aggregate Intrinsic Value, Ending balance	$ 8,166	$ 20,717	$ 14,512
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 6,111	$ 4,968

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	944,562	722,028
Granted, Number of Shares	387,347	503,052
Cancelled, Number of Shares	(122,178)	(44,900)
Vested, Number of Shares	(365,312)	(235,618)
Unvested, Number of Shares/Units, Ending balance	844,419	944,562
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 52.74	$ 39.77
Granted, Weighted Average Grant-Date Fair Value	55.38	62.67
Cancelled, Weighted Average Grant-Date Fair Value	57.02	49.55
Vested, Weighted Average Grant-Date Fair Value	47.18	34.93
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 55.76	$ 52.74

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	218,084	125,113
Granted, Number of Units	230,750	217,994
Cancelled, Number of Units	0	0
Vested, Number of Units	(175,235)	(125,023)
Unvested, Number of Shares/Units, Ending balance	273,599	218,084
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 56.97	$ 38.73
Granted, Weighted Average Grant-Date Fair Value	56.95	61.77
Cancelled, Weighted Average Grant-Date Fair Value	0	0
Vested, Weighted Average Grant-Date Fair Value	52.71	32.38
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 59.68	$ 56.97

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant-date fair value of options	$ 18.96	$ 21.78
Risk-free interest rate	1.40%	1.50%
Expected volatility	33.00%	35.00%
Expected life (in years)	5 years 6 months	5 years 6 months

Income Taxes - Components of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current:
Federal	$ 572	$ (218)	$ 30,834
State	(863)	4,078	3,959
Foreign	423	5,915	914
Total current	132	9,775	35,707
Deferred:
Federal	45,077	40,635	2,667
State	1,491	5,349	353
Foreign	(17,921)	(2,371)	4,195
Total deferred provision	28,647	43,613	7,215
Provision for (benefit from) income taxes	$ 28,779	$ 53,388	$ 42,922

Income Taxes - Effective Income Tax Rate (Detail)	12 Months Ended
Income Taxes - Effective Income Tax Rate (Detail)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
U.S. federal statutory rate on income before income taxes	35.00%	35.00%	35.00%
Impact of foreign operations	(13.50%)	(10.00%)	(4.20%)
Impact of foreign divestiture	39.20%
Effects of statutory rate change	(14.50%)
State income taxes, net of federal tax effect	7.50%	4.80%	2.30%
Permanent differences	8.30%	4.20%	1.10%
Transaction related items	25.90%
Change in valuation allowance	2.80%	1.20%	(0.10%)
Unrecognized tax benefit release	(7.20%)
Other	3.80%	(2.80%)	(0.10%)
Effective income tax rate	87.30%	32.40%	34.00%

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating losses and tax credit carryforwards - federal and state	$ 37,638	$ 47,695
Bad debt allowance	15,381	14,050
Accrued compensation and severance	23,379	20,150
Pension reserves	697	536
Insurance reserves	17,468	15,449
Leases	2,926	2,675
Accrued expenses		5,324
Other assets	2,038	3,551
Total gross deferred tax assets	99,527	109,430
Less: valuation allowance	(16,031)	(16,571)
Deferred tax assets	83,496	92,859
Deferred tax liabilities:
Fixed asset basis difference	(45,510)	(11,392)
Prepaid items	(1,324)	(3,113)
Intangible assets	(77,655)	(48,918)
Accrued expenses	(4,531)
Other liabilities	(29,216)	(4,258)
Total deferred tax liabilities	(158,236)	(67,681)
Total net deferred tax (liability)	$ (74,740)
Total net deferred tax asset		$ 25,178

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Examination [Line Items]
Valuation allowance against deferred tax assets	$ 16,031,000	$ 16,571,000
Domestic net operating loss carryforward	28,400,000	88,000,000
Foreign net operating loss carryforwards	92,200,000	14,700,000
State net operating loss carry forwards	$ 223,300,000	213,900,000
Operating loss carryforwards expiration start year	2031
Operating loss carryforwards expiration end year	2033
Expiration of State tax credits	2026
Income taxes receivable	$ 11,714,000	6,540,000
Income tax payable included in other accrued liabilities	527,000	7,367,000
Unrecognized tax benefits	6,949,000	4,511,000	$ 2,923,000	$ 1,893,000
Interest and penalties related to unrecognized tax benefits	$ 900,000	1,000,000
Maximum [Member]
Income Tax Examination [Line Items]
Exemption of tax credit	50.00%
Internal Revenue Service (IRS) [Member] \| Earliest Tax Year [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service	2014
Internal Revenue Service (IRS) [Member] \| Latest Tax Year [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service	2015
Payroll [Member] \| Maximum [Member]
Income Tax Examination [Line Items]
Exemption of tax credit	15.00%
Foreign Tax Authority [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum	2012
Period of examination by internal revenue service maximum	2015
State and Local Jurisdiction [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum	2011
Period of examination by internal revenue service maximum	2015
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits	$ 7,800,000	$ 5,400,000
Non US Subsidiaries [Member]
Income Tax Examination [Line Items]
Undistributed earnings of the foreign subsidiaries	$ 0

Income Taxes - Unrecognized Income Tax Benefits Net of Federal Benefit (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Balance at January 1	$ 4,511	$ 2,923	$ 1,893
Additions based on tax positions related to the current year		1,516
Additions for tax positions of prior years	5,427	2,874	1,030
Reductions as a result of the lapse of applicable statutes of limitations	(2,989)	(2,802)
Balance at December 31	$ 6,949	$ 4,511	$ 2,923

Derivatives - Additional Information (Detail)	1 Months Ended		12 Months Ended
Derivatives - Additional Information (Detail)	May 31, 2016 USD ($)	May 31, 2016 GBP (£)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	May 31, 2016 GBP (£)	Jul. 01, 2014 USD ($)	Mar. 12, 2013 USD ($)
Derivative [Line Items]
Gains (losses) associated with changes in fair value of the foreign currency forward contracts			$ 500,000	$ (1,900,000)
Cross currency swap assets			$ 73,100,000
6.125% Senior Notes Due 2021 [Member]
Derivative [Line Items]
Principal amount							$ 150,000,000
Debt instrument interest rate			6.125%	6.125%			6.125%
5.125% Senior Notes Due 2022 [Member]
Derivative [Line Items]
Principal amount						$ 300,000,000
Debt instrument interest rate			5.125%	5.125%		5.125%
5.625 % Senior Notes Due 2021 [Member]
Derivative [Line Items]
Debt instrument interest rate			5.625%
Cross Currency Swap Assets [Member]
Derivative [Line Items]
Notional amount	$ 650,000,000				£ 449,300,000
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 24,700,000
Derivative exchange rate	1.45				1.45
Cross Currency Swap Assets [Member] \| 6.125% Senior Notes Due 2021 [Member]
Derivative [Line Items]
Principal amount	$ 150,000,000
Debt instrument interest rate	6.125%				6.125%
Cross Currency Swap Assets [Member] \| 5.125% Senior Notes Due 2022 [Member]
Derivative [Line Items]
Principal amount	$ 300,000,000
Debt instrument interest rate	5.125%				5.125%
Cross Currency Swap Assets [Member] \| 5.625 % Senior Notes Due 2021 [Member]
Derivative [Line Items]
Principal amount	$ 200,000,000
Debt instrument interest rate	5.625%				5.625%

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liability (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative instruments	$ 73,509
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative instruments	73,509
Contingent consideration liabilities	107	$ 667
Fair Value [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,799,993	1,135,861
Fair Value [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	152,186	149,288
Fair Value [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	293,595	275,590
Fair Value [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	640,574	604,262
Fair Value [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	389,847
Fair Value [Member] \| 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	22,959	23,621
Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative instruments	73,509
Contingent consideration liabilities	107	667
Carrying Amount [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,799,993	1,135,861
Carrying Amount [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	147,574	147,082
Carrying Amount [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	295,442	294,749
Carrying Amount [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	640,574	639,431
Carrying Amount [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	381,268
Carrying Amount [Member] \| 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	$ 22,959	$ 23,621

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2016	Feb. 16, 2016	Dec. 31, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%		6.125%		6.125%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%		5.125%	5.125%
5.625 % Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%		9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%		9.50%

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Leased Assets [Line Items]
Rent expense	$ 73,348	$ 32,528	$ 12,201
Minimum [Member]
Operating Leased Assets [Line Items]
Original terms of the leases	5 years
Maximum [Member]
Operating Leased Assets [Line Items]
Original terms of the leases	10 years

Leases - Schedule of Aggregate Minimum Lease Payments under Non-cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Leases [Abstract]
2017	$ 65,259
2018	58,564
2019	54,211
2020	49,870
2021	46,799
Thereafter	768,607
Total minimum rental obligations	$ 1,043,310

Noncontrolling Interests - Additional Information (Detail) $ in Millions	May 02, 2016 USD ($) Partner	Aug. 31, 2015 USD ($)
Tennessee [Member] \| Crestwyn [Member]
Noncontrolling Interest [Line Items]
Number of noncontrolling partners \| Partner	2
Percentage of noncontrolling interests in the facility	40.00%
Equity ownership interests percentage in the facility	60.00%
Approximate value of noncontrolling interest	$ 6.0
Tennessee [Member] \| Crestwyn [Member] \| Partner One [Member]
Noncontrolling Interest [Line Items]
Percentage of noncontrolling interests in the facility	20.00%
Tennessee [Member] \| Crestwyn [Member] \| Partner Two [Member]
Noncontrolling Interest [Line Items]
Percentage of noncontrolling interests in the facility	20.00%
Massachusetts [Member] \| Southcoast Behavioral [Member]
Noncontrolling Interest [Line Items]
Percentage of noncontrolling interests in the facility		25.00%
Approximate value of noncontrolling interest		$ 9.2
Equity ownership interests percentage in the facility		75.00%

Segment Information - Additional Information (Detail)	12 Months Ended
Segment Information - Additional Information (Detail)	Dec. 31, 2016 State Beds Facilities
Segment Reporting Information [Line Items]
Number of facilities \| Facilities	573
Number of beds \| Beds	17,100
Number of operating states \| State	39
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facilities	208
Number of beds \| Beds	8,500
Number of operating states \| State	39
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facilities	365
Number of beds \| Beds	8,600

Segment Information - Summary of Financial Information by Operating Segment (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenue									$ 2,810,914	$ 1,794,492	$ 1,004,601
Segment EBITDA									608,590	404,832	215,488
Equity-based compensation expense									(28,345)	(20,472)	(10,058)
Debt extinguishment costs									(4,253)	(10,818)
Loss on divestiture									(178,809)
Gain (loss) on foreign currency derivatives									523	(1,926)	15,262
Transaction-related expenses									(48,323)	(36,571)	(13,650)
Interest expense, net									(181,325)	(106,742)	(48,221)
Depreciation and amortization									(135,103)	(63,550)	(32,667)
Income from continuing operations before income taxes	$ 42,438	$ (115,814)	$ 73,852	$ 32,479	$ 52,518	$ 41,645	$ 49,355	$ 21,205	32,955	164,753	126,154
U.S. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue									1,698,525	1,426,205	850,625
Segment EBITDA									443,341	377,587	209,668
U.K. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue									1,110,361	360,698	151,127
Segment EBITDA									245,046	90,035	39,832
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue									2,028	7,589	2,849
Segment EBITDA									$ (79,797)	$ (62,790)	$ (34,012)

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Goodwill:
Beginning balance	$ 2,128,215
Increase from 2016 acquisitions	781,794
Foreign currency translation loss	(127,020)
Loss on divestiture	(106,937)
Ending balance	2,681,188
Prior Year [Member]
Goodwill:
Prior year purchase price adjustments	5,136
U.S. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Beginning balance	1,941,873
Increase from 2016 acquisitions	95,645
Loss on divestiture	(85)
Ending balance	2,041,795
U.S. Facilities [Member] \| Operating Segment [Member] \| Prior Year [Member]
Goodwill:
Prior year purchase price adjustments	4,362
U.K. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Beginning balance	186,342
Increase from 2016 acquisitions	686,149
Foreign currency translation loss	(127,020)
Loss on divestiture	(106,852)
Ending balance	639,393
U.K. Facilities [Member] \| Operating Segment [Member] \| Prior Year [Member]
Goodwill:
Prior year purchase price adjustments	$ 774

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Assets:
Assets	$ 6,024,726	$ 4,279,208
U.S. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	3,382,167	3,061,519
U.K. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	2,441,018	1,045,922
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Assets:
Assets	$ 201,541	$ 171,767

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 2,703,695	$ 1,709,053
Operating Segment [Member] \| U.S. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,000,000	832,200
Operating Segment [Member] \| U.K. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,700,000	824,400
Corporate Reconciling Items and Eliminations [Member] \| Corporate and Other [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 27,100	$ 52,400

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, employer discretionary contribution amount	$ 0.1	$ 0.1	$ 0.1
Employee benefit plan, Accumulated other comprehensive income (loss)	(7.4)	2.6	(2.8)
Employee benefit plan, Accumulated other comprehensive income (loss) , Net	(6.1)	1.7	$ (2.2)
Partnerships in Care Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Pension liability under defined benefit pension plan	$ 10.7	$ 2.8

Employee Benefit Plans - Summary of Funded Status (Unfunded Liability) of Partnerships in Care Pension Plan Based Upon Actuarial Valuations (Detail) - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 64,162	$ 58,107
Fair value of plan assets	53,462	55,286
Unfunded liability	$ 10,700	$ 2,821	$ 9,554

Employee Benefit Plans - Summary of Changes in Partnerships in Care Pension Plan Net Pension Liability (Detail) - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Net pension liability at beginning of period	$ 2,821	$ 9,554
Employer contributions	(740)	(1,217)
Net pension expense (benefit)	339	(419)
Pension liability adjustment	8,781	(4,661)
Foreign currency translation loss	(501)	(436)
Net pension liability at end of period	$ 10,700	$ 2,821

Employee Benefit Plans - Summary of Assumptions Used to Determine Plan Benefit Obligation (Detail) - Partnership in Care Benefits Plan [Member]	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.70%	3.80%
Compensation increase rate	2.40%	2.20%

Employee Benefit Plans - Summary of Components of Net Pension Plan Expense (Detail) - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Interest cost on projected benefit obligation	$ 1,964	$ 2,369
Service cost on projected benefit obligation		616
Curtailments on projected benefit obligation		(1,373)
Expected return on assets	(1,625)	(2,031)
Total pension plan expense (benefit)	$ 339	$ (419)

Employee Benefit Plans - Summary of Assumptions Used to Determine Net Periodic Pension Plan Expense (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Discount rate	2.70%	3.80%
Expected long-term rate of return on plan assets	2.70%	3.80%

Employee Benefit Plans - Schedule of Weighted-Average Asset Allocation by Asset Category in Partnerships in Care Pension Plan (Detail) - Partnership in Care Benefits Plan [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	1.50%	1.70%
U.K. Government Obligation [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	14.50%	3.80%
Annuity Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	41.60%	46.50%
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	26.30%	35.70%
Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	12.10%	8.50%
Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	4.00%	3.80%

Other Comprehensive Loss - Components Of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 1,683,028	$ 880,965	$ 480,710
Foreign currency translation loss	(477,772)	(40,103)	(66,206)
Gain on derivative instruments, net of tax of $29.1 million	40,598
Pension liability adjustment, net of tax of $1.3 million, $0.9 million and $0.6 million, respectively	(7,749)	3,826	(2,164)
Balance	2,167,724	1,683,028	880,965
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(106,309)	(66,206)
Foreign currency translation loss	(477,772)	(40,103)	(66,206)
Balance	(584,081)	(106,309)	(66,206)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain on derivative instruments, net of tax of $29.1 million	40,598
Balance	40,598
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	1,662	(2,164)
Pension liability adjustment, net of tax of $1.3 million, $0.9 million and $0.6 million, respectively	(7,749)	3,826	(2,164)
Balance	(6,087)	1,662	(2,164)
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(104,647)	(68,370)
Foreign currency translation loss	(477,772)	(40,103)	(66,206)
Gain on derivative instruments, net of tax of $29.1 million	40,598
Pension liability adjustment, net of tax of $1.3 million, $0.9 million and $0.6 million, respectively	(7,749)	3,826	(2,164)
Balance	$ (549,570)	$ (104,647)	$ (68,370)

Other Comprehensive Loss - Components Of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain on derivative instruments, tax	$ 29.1	$ 0.0	$ 0.0
Pension liability adjustment, tax	1.3	0.9	0.6
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain on derivative instruments, tax	29.1
Pension liability adjustment, tax	$ 1.3	$ 0.9	$ 0.6

Quarterly Information (Unaudited) - Schedule of Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 702,888	$ 734,665	$ 756,548	$ 616,813	$ 495,319	$ 479,730	$ 453,660	$ 365,783	$ 2,852,823	$ 1,829,619	$ 1,030,784
Income from continuing operations before income taxes	42,438	(115,814)	73,852	32,479	52,518	41,645	49,355	21,205	32,955	164,753	126,154
Net income attributable to Acadia Healthcare Company, Inc. stockholders	$ 41,818	$ (117,808)	$ 56,445	$ 25,688	$ 34,566	$ 29,550	$ 33,844	$ 14,594	$ 6,143	$ 112,554	$ 83,040
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 0.49	$ 0.42	$ 0.50	$ 0.23	$ 0.07	$ 1.65	$ 1.51
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 0.49	$ 0.42	$ 0.49	$ 0.23	$ 0.07	$ 1.64	$ 1.50

Quarterly Information (Unaudited) - Schedule of Quarterly Financial Information (Parenthetical) (Detail) - USD ($) $ in Thousands			3 Months Ended		12 Months Ended
	Nov. 01, 2015	Sep. 21, 2015	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information [Line Items]
Debt extinguishment costs					$ (4,253)	$ (10,818)
Loss on divestiture					(178,809)
12.875% Senior Notes Due 2018 [Member]
Quarterly Financial Information [Line Items]
Debt extinguishment costs	$ 800	$ 10,000
Debt extinguishment costs, net of taxes		6,800
Redemption amount	$ 9,200	$ 88,300
Debt instrument interest rate	12.875%	12.875%
Redemption amount	$ 9,200	$ 88,300
Senior notes interest percentage	12.875%	12.875%
TLB Facility [Member]
Quarterly Financial Information [Line Items]
Debt extinguishment costs				$ 3,400
Debt extinguishment costs, net of taxes				142,000
Refinancing Amendment [Member]
Quarterly Financial Information [Line Items]
Debt extinguishment costs			$ 800
Debt extinguishment costs, net of taxes			3,100
U.K. Disposal Group [Member]
Quarterly Financial Information [Line Items]
Loss on divestiture				$ 174,700	$ 175,000
Divestiture [Member]
Quarterly Financial Information [Line Items]
Loss on divestiture			$ 4,000

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Dec. 31, 2016	Feb. 16, 2016	Dec. 31, 2015	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%		6.125%				6.125%
5.125% Senior Notes Due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%		5.125%			5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%		5.625%	5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%	6.50%

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 57,063	$ 11,215	$ 94,040	$ 4,569
Accounts receivable, net	263,327	216,626
Other current assets	107,537	66,895
Total current assets	427,927	294,736
Property and equipment, net	2,703,695	1,709,053
Goodwill	2,681,188	2,128,215
Intangible assets, net	83,310	59,575
Deferred tax assets - noncurrent	3,780	49,114
Derivative instruments	73,509
Other assets	51,317	38,515
Total assets	6,024,726	4,279,208
Current liabilities:
Current portion of long-term debt	34,805	45,360
Accounts payable	80,034	91,341
Accrued salaries and benefits	105,068	80,696
Other accrued liabilities	122,958	72,806
Total current liabilities	342,865	290,203
Long-term debt	3,253,004	2,195,384
Deferred tax liabilities - noncurrent	78,520	23,936
Other liabilities	164,859	78,602
Total liabilities	3,839,248	2,588,125
Redeemable noncontrolling interests	17,754	8,055
Total equity	2,167,724	1,683,028	880,965	480,710
Total liabilities and equity	6,024,726	4,279,208
Consolidating Adjustments [Member]
Current assets:
Cash and cash equivalents				(1,925)
Deferred tax assets - noncurrent	(14,348)
Investment in subsidiaries	(4,885,865)	(3,495,067)
Other assets	(489,646)	(424,024)
Total assets	(5,389,859)	(3,919,091)
Current liabilities:
Long-term debt	(489,646)	(424,024)
Deferred tax liabilities - noncurrent	(14,348)
Total liabilities	(503,994)	(424,024)
Total equity	(4,885,865)	(3,495,067)
Total liabilities and equity	(5,389,859)	(3,919,091)
Parent [Member]
Current assets:
Deferred tax assets - noncurrent	13,522	3,946
Derivative instruments	73,509
Investment in subsidiaries	4,885,865	3,495,067
Other assets	493,294	427,270
Total assets	5,466,190	3,926,283
Current liabilities:
Current portion of long-term debt	34,550	45,125
Other accrued liabilities	33,616	26,132
Total current liabilities	68,166	71,257
Long-term debt	3,230,300	2,171,998
Total liabilities	3,298,466	2,243,255
Total equity	2,167,724	1,683,028
Total liabilities and equity	5,466,190	3,926,283
Combined Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	15,681	1,987	76,685
Accounts receivable, net	209,124	187,546
Other current assets	61,724	57,968
Total current assets	286,529	247,501
Property and equipment, net	940,880	805,439
Goodwill	1,935,260	1,835,339
Intangible assets, net	56,676	57,024
Deferred tax assets - noncurrent		40,587
Other assets	40,480	32,947
Total assets	3,259,825	3,018,837
Current liabilities:
Accounts payable	49,205	75,015
Accrued salaries and benefits	72,835	66,249
Other accrued liabilities	24,375	10,886
Total current liabilities	146,415	152,150
Deferred tax liabilities - noncurrent	40,574
Other liabilities	101,938	75,159
Total liabilities	288,927	227,309
Total equity	2,970,898	2,791,528
Total liabilities and equity	3,259,825	3,018,837
Combined Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	41,382	9,228	$ 17,355	$ 6,494
Accounts receivable, net	54,203	29,080
Other current assets	45,813	8,927
Total current assets	141,398	47,235
Property and equipment, net	1,762,815	903,614
Goodwill	745,928	292,876
Intangible assets, net	26,634	2,551
Deferred tax assets - noncurrent	4,606	4,581
Other assets	7,189	2,322
Total assets	2,688,570	1,253,179
Current liabilities:
Current portion of long-term debt	255	235
Accounts payable	30,829	16,326
Accrued salaries and benefits	32,233	14,447
Other accrued liabilities	64,967	35,788
Total current liabilities	128,284	66,796
Long-term debt	512,350	447,410
Deferred tax liabilities - noncurrent	52,294	23,936
Other liabilities	62,921	3,443
Total liabilities	755,849	541,585
Redeemable noncontrolling interests	17,754	8,055
Total equity	1,914,967	703,539
Total liabilities and equity	$ 2,688,570	$ 1,253,179

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	$ 702,888	$ 734,665	$ 756,548	$ 616,813	$ 495,319	$ 479,730	$ 453,660	$ 365,783	$ 2,852,823	$ 1,829,619	$ 1,030,784
Provision for doubtful accounts									(41,909)	(35,127)	(26,183)
Revenue									2,810,914	1,794,492	1,004,601
Salaries, wages and benefits									1,541,854	973,732	575,412
Professional fees									185,486	116,463	52,482
Supplies									117,425	80,663	48,422
Rents and leases									73,348	32,528	12,201
Other operating expenses									312,556	206,746	110,654
Depreciation and amortization									135,103	63,550	32,667
Interest expense, net									181,325	106,742	48,221
Debt extinguishment costs									4,253	10,818
Loss on divestiture									178,809
Loss (gain) on foreign currency derivatives									(523)	1,926	(15,262)
Transaction-related expenses									48,323	36,571	13,650
Total expenses									2,777,959	1,629,739	878,447
(Loss) income from continuing operations before income taxes	42,438	(115,814)	73,852	32,479	52,518	41,645	49,355	21,205	32,955	164,753	126,154
(Benefit from) provision for income taxes									28,779	53,388	42,922
Income (loss) from continuing operations									4,176	111,365	83,232
Income (loss) from discontinued operations, net of income taxes										111	(192)
Net income (loss)									4,176	111,476	83,040
Net loss attributable to noncontrolling interests									1,967	1,078
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 41,818	$ (117,808)	$ 56,445	$ 25,688	$ 34,566	$ 29,550	$ 33,844	$ 14,594	6,143	112,554	83,040
Other comprehensive loss (income):
Foreign currency translation (loss) gain									(477,772)	(40,103)	(66,206)
Gain on derivative instruments									40,598
Pension liability adjustment, net									(7,749)	3,826	(2,164)
Other comprehensive loss (income)									(444,923)	(36,277)	(68,370)
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.									(438,780)	76,277	14,670
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in earnings of subsidiaries									(65,560)	(176,178)	(97,414)
Income (loss) from continuing operations									(65,560)	(176,178)	(97,414)
Net income (loss)									(65,560)	(176,178)	(97,414)
Net income (loss) attributable to Acadia Healthcare Company, Inc.									(65,560)	(176,178)
Other comprehensive loss (income):
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.									(65,560)	(176,178)	(97,414)
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Salaries, wages and benefits									28,345	20,472	10,058
Interest expense, net									50,921	68,533	27,199
Debt extinguishment costs									4,253	10,818
Loss (gain) on foreign currency derivatives									(523)	1,926	(15,262)
Total expenses									82,996	101,749	21,995
(Loss) income from continuing operations before income taxes									(82,996)	(101,749)	(21,995)
Equity in earnings of subsidiaries									65,560	176,178	97,414
(Benefit from) provision for income taxes									(21,612)	(37,047)	(7,621)
Income (loss) from continuing operations									4,176	111,476	83,040
Net income (loss)									4,176	111,476	83,040
Net income (loss) attributable to Acadia Healthcare Company, Inc.									4,176	111,476
Other comprehensive loss (income):
Gain on derivative instruments									40,598
Other comprehensive loss (income)									40,598
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.									44,774	111,476	83,040
Combined Subsidiary Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts									1,662,734	1,415,016	826,465
Provision for doubtful accounts									(38,349)	(32,614)	(23,866)
Revenue									1,624,385	1,382,402	802,599
Salaries, wages and benefits									865,104	726,215	459,297
Professional fees									89,062	83,422	38,632
Supplies									76,246	65,077	40,511
Rents and leases									34,540	29,094	10,136
Other operating expenses									206,308	170,018	83,835
Depreciation and amortization									58,018	41,768	22,990
Interest expense, net									75,848	17,476	6,207
Loss on divestiture									778
Transaction-related expenses									32,173	24,914	12,367
Total expenses									1,438,077	1,157,984	673,975
(Loss) income from continuing operations before income taxes									186,308	224,418	128,624
(Benefit from) provision for income taxes									68,335	85,765	44,608
Income (loss) from continuing operations									117,973	138,653	84,016
Income (loss) from discontinued operations, net of income taxes										111	(192)
Net income (loss)									117,973	138,764	83,824
Net income (loss) attributable to Acadia Healthcare Company, Inc.									117,973	138,764
Other comprehensive loss (income):
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.									117,973	138,764	83,824
Combined Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts									1,190,089	414,603	204,319
Provision for doubtful accounts									(3,560)	(2,513)	(2,317)
Revenue									1,186,529	412,090	202,002
Salaries, wages and benefits									648,405	227,045	106,057
Professional fees									96,424	33,041	13,850
Supplies									41,179	15,586	7,911
Rents and leases									38,808	3,434	2,065
Other operating expenses									106,248	36,728	26,819
Depreciation and amortization									77,085	21,782	9,677
Interest expense, net									54,556	20,733	14,815
Loss on divestiture									178,031
Transaction-related expenses									16,150	11,657	1,283
Total expenses									1,256,886	370,006	182,477
(Loss) income from continuing operations before income taxes									(70,357)	42,084	19,525
(Benefit from) provision for income taxes									(17,944)	4,670	5,935
Income (loss) from continuing operations									(52,413)	37,414	13,590
Net income (loss)									(52,413)	37,414	13,590
Net loss attributable to noncontrolling interests									1,967	1,078
Net income (loss) attributable to Acadia Healthcare Company, Inc.									(50,446)	38,492
Other comprehensive loss (income):
Foreign currency translation (loss) gain									(477,772)	(40,103)	(66,206)
Pension liability adjustment, net									(7,749)	3,826	(2,164)
Other comprehensive loss (income)									(485,521)	(36,277)	(68,370)
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.									$ (535,967)	$ 2,215	$ (54,780)

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Cash Flows (Detail) $ in Thousands, £ in Millions		12 Months Ended
	Nov. 30, 2016 GBP (£)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Operating activities:
Net income (loss)		$ 4,176	$ 111,476	$ 83,040
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization		135,103	63,550	32,667
Amortization of debt issuance costs		10,324	6,709	3,198
Equity-based compensation expense		28,345	20,472	10,058
Deferred income tax (benefit) expense		28,647	43,613	7,215
Loss from discontinued operations, net of taxes			(111)	192
Debt extinguishment costs		4,253	10,818
Loss on divestiture		178,809
(Gain) loss on foreign currency derivatives		(523)	1,926	(15,262)
Other		4,715	1,615	488
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		(15,718)	(24,954)	(15,110)
Other current assets		(20,648)	(2,717)	(2,011)
Other assets		(4,354)	(8,021)	(6,513)
Accounts payable and other accrued liabilities		22,693	6,868	2,793
Accrued salaries and benefits		(8,572)	1,658	11,980
Other liabilities		4,484	9,236	2,749
Net cash (used in) provided by continuing operating activities		371,734	242,138	115,484
Net cash (used in) provided by discontinued operating activities		(10,256)	(1,735)	(198)
Net cash (used in) provided by operating activities		361,478	240,403	115,286
Investing activities:
Cash paid for acquisitions, net of cash acquired		(683,455)	(574,777)	(738,702)
Cash paid for capital expenditures		(307,472)	(276,047)	(113,244)
Cash paid for real estate acquisitions		(40,757)	(26,622)	(23,177)
Settlement of foreign currency derivatives		523	(1,926)	15,262
Cash received for divestiture	£ 320	373,266
Other		(2,470)	(5,099)	(913)
Net cash used in investing activities		(660,365)	(884,471)	(860,774)
Financing activities:
Borrowings on long-term debt		1,480,000	1,150,000	542,500
Borrowings on revolving credit facility		179,000	468,000	230,500
Principal payments on revolving credit facility		(337,000)	(310,000)	(284,000)
Principal payments on long-term debt		(49,941)	(31,965)	(7,695)
Repayment of assumed CRC debt		(1,348,389)	(904,467)
Repayment of long-term debt		(200,594)	(97,500)
Repayments of senior notes			(97,500)
Payment of debt issuance costs		(36,649)	(26,421)	(12,993)
Payment of premium on senior notes			(7,480)
Issuance of common stock, net		685,097	331,308	374,431
Common stock withheld for minimum statutory taxes, net		(8,846)	(7,762)	(4,099)
Excess tax benefit from equity awards			309	4,617
Cash paid for contingent consideration				(5,000)
Other		(3,837)	(420)	(289)
Net cash provided by (used in) financing activities		358,841	563,602	837,972
Effect of exchange rate changes on cash		(14,106)	(2,359)	(3,013)
Net (decrease) increase in cash and cash equivalents		45,848	(82,825)	89,471
Cash and cash equivalents at beginning of the period		11,215	94,040	4,569
Cash and cash equivalents at end of the period		57,063	11,215	94,040
Consolidating Adjustments [Member]
Operating activities:
Net income (loss)		(65,560)	(176,178)	(97,414)
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		65,560	176,178	97,414
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets		3,109	1,100	1,151
Net cash (used in) provided by continuing operating activities		3,109	1,100	1,151
Net cash (used in) provided by operating activities		3,109	1,100	1,151
Financing activities:
Principal payments on long-term debt		296,109	1,315	1,151
Cash (used in) provided by intercompany activity		(299,218)	(2,415)	(377)
Net cash provided by (used in) financing activities		(3,109)	(1,100)	774
Net (decrease) increase in cash and cash equivalents				1,925
Cash and cash equivalents at beginning of the period				(1,925)
Parent [Member]
Operating activities:
Net income (loss)		4,176	111,476	83,040
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(65,560)	(176,178)	(97,414)
Amortization of debt issuance costs		10,751	7,147	2,748
Equity-based compensation expense		28,345	20,472	10,058
Deferred income tax (benefit) expense		(2,172)	617	(1,969)
Debt extinguishment costs		4,253	10,818
(Gain) loss on foreign currency derivatives		(523)	1,926	(15,262)
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets		(3,109)	(1,100)	(1,151)
Net cash (used in) provided by continuing operating activities		(23,839)	(24,822)	(19,950)
Net cash (used in) provided by operating activities		(23,839)	(24,822)	(19,950)
Investing activities:
Settlement of foreign currency derivatives				15,262
Cash received for divestiture		370,000
Net cash used in investing activities		370,000		15,262
Financing activities:
Borrowings on long-term debt		1,480,000	1,150,000	542,500
Borrowings on revolving credit facility		179,000	468,000	230,500
Principal payments on revolving credit facility		(337,000)	(310,000)	(284,000)
Principal payments on long-term debt		(49,706)	(31,965)	(7,500)
Repayment of assumed CRC debt		(1,348,389)	(904,467)
Repayment of long-term debt		(200,594)
Repayments of senior notes			(97,500)
Payment of debt issuance costs		(36,649)	(26,421)	(12,993)
Payment of premium on senior notes			(7,480)
Issuance of common stock, net		685,097	331,308	374,431
Common stock withheld for minimum statutory taxes, net		(8,846)	(7,762)	(4,099)
Excess tax benefit from equity awards			309	4,617
Other		(1,149)
Cash (used in) provided by intercompany activity		(707,925)	(539,200)	(838,768)
Net cash provided by (used in) financing activities		(346,161)	24,822	4,688
Combined Subsidiary Guarantors [Member]
Operating activities:
Net income (loss)		117,973	138,764	83,824
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization		58,018	41,768	22,990
Deferred income tax (benefit) expense		50,611	42,246	5,231
Loss from discontinued operations, net of taxes			(111)	192
Loss on divestiture		778
Other		4,022	1,582	449
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		(24,017)	(18,632)	(13,636)
Other current assets		(3,138)	(1,152)	(2,205)
Other assets		(4,048)	(8,567)	(6,910)
Accounts payable and other accrued liabilities		(45,552)	(7,583)	(5,559)
Accrued salaries and benefits		3,844	312	11,035
Other liabilities		4,050	9,350	1,769
Net cash (used in) provided by continuing operating activities		162,541	197,977	97,180
Net cash (used in) provided by discontinued operating activities		(10,256)	(1,735)	(198)
Net cash (used in) provided by operating activities		152,285	196,242	96,982
Investing activities:
Cash paid for acquisitions, net of cash acquired		(103,359)	(254,848)	(723,064)
Cash paid for capital expenditures		(177,593)	(172,329)	(83,864)
Cash paid for real estate acquisitions		(28,956)	(25,293)	(23,177)
Settlement of foreign currency derivatives		523	(1,926)
Cash received for divestiture		7,859
Other		(1,573)	(5,099)	(913)
Net cash used in investing activities		(303,099)	(459,495)	(831,018)
Financing activities:
Principal payments on long-term debt		(293,000)
Cash paid for contingent consideration				(5,000)
Other		(2,688)	(420)	(289)
Cash (used in) provided by intercompany activity		460,196	191,334	816,010
Net cash provided by (used in) financing activities		164,508	190,914	810,721
Effect of exchange rate changes on cash			(2,359)
Net (decrease) increase in cash and cash equivalents		13,694	(74,698)	76,685
Cash and cash equivalents at beginning of the period		1,987	76,685
Cash and cash equivalents at end of the period		15,681	1,987	76,685
Combined Non-Guarantors [Member]
Operating activities:
Net income (loss)		(52,413)	37,414	13,590
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization		77,085	21,782	9,677
Amortization of debt issuance costs		(427)	(438)	450
Deferred income tax (benefit) expense		(19,792)	750	3,953
Loss on divestiture		178,031
Other		693	33	39
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		8,299	(6,322)	(1,474)
Other current assets		(17,510)	(1,565)	194
Other assets		(306)	546	397
Accounts payable and other accrued liabilities		68,245	14,451	8,352
Accrued salaries and benefits		(12,416)	1,346	945
Other liabilities		434	(114)	980
Net cash (used in) provided by continuing operating activities		229,923	67,883	37,103
Net cash (used in) provided by operating activities		229,923	67,883	37,103
Investing activities:
Cash paid for acquisitions, net of cash acquired		(580,096)	(319,929)	(15,638)
Cash paid for capital expenditures		(129,879)	(103,718)	(29,380)
Cash paid for real estate acquisitions		(11,801)	(1,329)
Cash received for divestiture		(4,593)
Other		(897)
Net cash used in investing activities		(727,266)	(424,976)	(45,018)
Financing activities:
Principal payments on long-term debt		(3,344)	(1,315)	(1,346)
Cash (used in) provided by intercompany activity		546,947	350,281	23,135
Net cash provided by (used in) financing activities		543,603	348,966	21,789
Effect of exchange rate changes on cash		(14,106)		(3,013)
Net (decrease) increase in cash and cash equivalents		32,154	(8,127)	10,861
Cash and cash equivalents at beginning of the period		9,228	17,355	6,494
Cash and cash equivalents at end of the period		$ 41,382	$ 9,228	$ 17,355